

Fig. 2. Vascularization of the reconstructed endometrium predominantly composed of human–mouse chimeric vessels. Immunofluorescence staining of the reconstituted endometrial tissue (A) and the mouse kidney parenchyma adjacent to the reconstituted tissue (B–E) in the $E_2 + P_4$ -treated NOG mice by using antibodies against human CD31 (hCD31) and murine CD31 (mCD31) (A), hCD31 and TER-119 (B), hCD31 and Vm (C), Vm and α SMA (D), or mCD31 and Vm (E), followed by Hoechst (Ho) staining. (A) Arrows and arrowheads indicate hCD31⁺ cells and mCD31⁺ cells, respectively. (B) Arrowheads show hCD31⁺ vessels containing mouse erythrocytes positive for TER-119. (D) A small box marks a region shown at higher magnification in the adjacent panel as indicated. (E) Arrowheads point to mCD31⁺ vessels that were present together with human Vm⁺ cells. (Scale bars: 100 μ m.)

Intriguingly, cells positive for TER-119, a mouse erythrocyte marker, were found not only in the mouse CD31⁺ vessels (SI Fig. 7) but also in the vessels consisting of human CD31⁺ endothelial cells (Fig. 2B, arrowheads), indicating that the human-originated vasculature functioned as a circulation system in the reconstructed endometrium.

To address the presence of chimeric vessels composed of human and mouse endothelial cells, we performed histological analyses focusing on the mouse kidney adjacent to the reconstituted endometrium. We found that human-originated (human Vm-positive) cells migrated into the mouse kidney parenchyma and most were positive for human CD31 (Fig. 2C). The anti-

α SMA antibody reacts with both mouse and human smooth muscle cells. Therefore, as most Vm⁺ cells also are positive for human CD31, α SMA⁻/Vm⁺ cells (Fig. 2D, green) corresponded to human CD31⁺ cells in the mouse kidney parenchyma, whereas α SMA⁺/Vm⁻ cells (Fig. 2D, red) were mouse smooth muscle cells. Thus, there existed chimeric vessels of two distinct species in the mouse kidney parenchyma (Fig. 2D Center and Right), which was confirmed by the colocalization of murine CD31⁺ endothelial cells and human Vm-positive cells (Fig. 2E, arrowheads).

Hormone-Dependent Changes of the Reconstructed Endometrium. It is well known that the endometrial P₄ receptor (PR) is up-regulated by E₂ exposure. In agreement, PR was expressed prominently in the E₂-exposed reconstruct (Fig. 3A). In addition, glandular cells became pseudostratified (Fig. 3A, arrowheads), reflecting a high level of E₂-dependent proliferation activity.

Decidualization is the P₄-induced differentiation of E₂-primed endometrial stromal cells, which occurs during the P₄-dominated secretory phase and pregnancy. Decidualized stromal cells become enlarged and round, and they produce many bioactive substances, including prolactin (PRL) (10). Accordingly, PRL was expressed prominently in the stromal cells, but not glandular cells, of E₂ + P₄-exposed endometrial reconstructs (Fig. 3B), indicating the successful spatiotemporal induction of PRL in this animal model. In addition to the strong staining of PRL caused by relatively high levels of P₄, H&E staining revealed edematous stroma with predecidual changes, accumulation of mononuclear leukocytes beneath the glandular epithelium, and tortuous glands (SI Fig. 8), all of which are distinctive morphological changes of secretory-phase endometrium.

One of the unique events of human cycling endometrium is the breakdown and shedding of tissue, i.e., menstruation, which is induced by the withdrawal of P₄. To provoke menstrual changes in the reconstructed endometrium, OVX-NOG mice were subjected to cyclic treatment with E₂ + P₄ (cyclic E₂ + P₄) after xenotransplantation and thereafter to P₄ withdrawal (Fig. 3C). Grafts collected a week after the second P₄ withdrawal contained large blood-filled cysts that were similar to red spot lesions (Fig. 3D, arrowheads) typical of aggressive endometriosis (11). H&E and immunofluorescence staining of the cystic lesion revealed that the glandular structures partly were destroyed (Fig. 3E, arrowheads) and that hemorrhage had occurred in the degenerative stroma (Fig. 3E, arrow).

Lentiviral Introduction of Reporter Genes into Primary Endometrial Cells. Bioluminescence imaging (BLI) recently has emerged as a useful tool for tumor, hematopoietic, and neural cell tracking




Fig. 3. Hormone-dependent morphological and functional changes of the reconstructed endometrium. Immunofluorescence staining of the reconstituted endometrial tissues in the E₂-treated (A) or E₂ + P₄-treated (B) NOG mice by using antibodies against PR and Vm (A) and Vm and PRL (B), followed by Hoechst (Ho) staining. (A) Arrowheads show pseudostratified glandular cells. (C) Hormonal treatment protocol (cyclic E₂ + P₄) for induction of menstruation-like tissue breakdown and shedding. (D) Macroscopic findings of the transplanted site (arrows) of a NOG mouse treated with cyclic E₂ + P₄. (E) H&E and immunofluorescence staining of the transplanted lesion in the cyclic E₂ + P₄-treated mice. The glandular structure was partially disrupted (arrowheads), and hemorrhage occurred in the stroma (arrow). (B and E) A small box marks a region shown at higher magnification in the adjacent panel as indicated. (Scale bars: 100 μ m.)




Fig. 4. Expression of both fluorescence and luminescence markers in the lentivirally transduced SDECs. (A) Phase-contrast and fluorescence microscopy of the primary cultures of lentivirally transduced endometrial stromal (Upper) and glandular (Lower) cells. (B) A representative flow cytometric profile of the PI-negative fraction (red box at Left) of the lentivirally transduced SDECs consisting of three subpopulations (Right) based on the fluorescence intensity: high (I), low (II), and negative (III) subpopulations. (C) Macroscopic luminescence image of a six-well dish where each subpopulation, as sorted in B, was cultured in the corresponding well. Noninfected SDECs were cultured in the "IV" well.

studies in living animals (12–15). To apply this animal model to the BLI system, we have developed a recombinant lentivirus capable of introducing and stably expressing both the Venus [a yellow fluorescent protein (YFP) mutant] (16) gene and the click beetle red-emitting luciferase (CBR luc, a luciferase variant) (17) gene in the primary culture endometrial cells. These two reporter markers are useful for cell sorting and the detection of living cells from outside the body.

Fluorescence microscopy revealed YFP signals were detected in ≈ 20 –60% of the primary culture SDECs infected with the recombinant lentivirus (Fig. 4A). To quantitatively assess YFP intensity, these SDECs were harvested and stained with propidium iodide (PI). Then, PI-negative SDECs were sorted by flow cytometry and further divided into three groups based on YFP intensity: high (I), low (II), and negative (III) (Fig. 4B). These three subpopulations and noninfected SDECs (IV) were plated onto the corresponding wells of a six-well dish, cultured, and subjected to BLI (Fig. 4C). BLI revealed the luminescence intensity to correlate well with the YFP intensity (Fig. 4C).

Noninvasive and Quantitative Assessment of the Reconstituted Endometrium by BLI. The OVX-NOG mice were transplanted with the lentivirally engineered SDECs expressing CBR luc beneath the kidney capsule, simultaneously implanted with two E_2 pellets, and subjected to BLI analysis 8 weeks after xenotransplantation. BLI of the ventrally positioned NOG mouse revealed bioluminescence signals in locations corresponding to the bilateral kidney (Fig. 5A Upper). To confirm that these signals did indeed originate from the transplanted kidney, a dorsally positioned laparotomized mouse (Fig. 5A Lower Left) and its excised kidneys (Fig. 5A Lower Right) were subjected to BLI, which clearly indicated that the intense focal bioluminescent spots were confined to the transplanted sites.

To determine whether the growth behavior of the reconstructed tissue can be assessed quantitatively and sequentially, we treated the xenotransplanted OVX-NOG mice without or with one or two E_2 pellets. Sequential BLI of the mice at 3–9 weeks after xenotransplantation revealed that the signal inten-

sities reflecting the volume of the reconstructed tissue were enhanced in an E_2 dose- and time-dependent manner (Fig. 5B), in agreement with the macroscopic findings (SI Fig. 6). In contrast, the signal intensity was kept low and constant or rather decreased in nonhormonally treated mice (Fig. 5B).

To validate our BLI system as a tool for drug testing, we measured the bioluminescence signals in xenotransplanted OVX-NOG mice treated with E_2 in combination with ICI 182,780 (Tocris Cookson Inc., Ellisville, MO), a pure estrogen antagonist. In contrast to the mice treated with E_2 alone (Fig. 5B), the signal intensity was decreased 2–3 months after the cotreatment with E_2 and ICI 182,780 (Fig. 5C), indicating that the antagonistic effect of ICI 182,780 can be assessed noninvasively.

Finally, we monitored the dynamic changes of the endometrial reconstructs during an artificial menstrual cycle induced by cyclic $E_2 + P_4$ treatment (Fig. 5D). Sequential BLI revealed that the signal intensities fluctuated dramatically in accord with the addition and withdrawal of P_4 (Fig. 5D), indicating that the decrease and reincrease in signal intensity faithfully reflected tissue breakdown and regression after P_4 withdrawal as shown in Fig. 3 C and D and, presumably, subsequent tissue regeneration, respectively (Fig. 5D). Thus, the repeated menstrual cycle-related changes of the transplants can be noninvasively monitored in living NOG mice.

Discussion

Human endometrium is believed to regenerate from the lower basalis layer, a germinal compartment that persists after menstruation, to give rise to a new functionalis layer (18). The potential of singly dissociated endometrial cells to reconstitute the endometrial tissue raises a possibility that endometrial stem/progenitor cells present in the functionalis layer also may participate in the physiological regeneration of the endometrium through their recycle and reuse. Our hypothesis seems to be supported by the recent report that label-retaining cells, which are thought to be tissue stem/progenitor cells, are present not only at the endometrial-myometrial junction but also in luminal epithelium and stroma adjacent to luminal epithelium and near blood vessels in mice (19).

Several experiments in which human endometrial tissues were transplanted into immunodeficient mice such as SCID and nude mice have shown that endometriotic lesions derive their blood supply from the surrounding vascular network (20–22). Furthermore, native human-originated graft vessels disappear gradually, but host vessels instead invade during revascularization of endometrial explants (21–24). As NK cells play a critical role in the IL-12-mediated inhibition of angiogenesis (25), the lack of human endometrial graft-originated vessels in SCID and nude mice in previous studies (20–24) may be attributable to the presence of functioning NK cells, which would attack various immature precursor cells that show low MHC expression level (26). In contrast, we demonstrate here that human-derived vessels are abundant in the endometrial reconstructs, and that they invade into the mouse kidney parenchyma and become connected with mouse vessels functioning as a circulation system. Because NK cells are functionally incompetent in the NOG mouse (5), the human-originated neovascularization is allowed to take place. Given that impaired NK cell cytotoxicity contributes to inadequate removal of ectopic endometrial cells from the peritoneal cavity (27), this endometriosis model using NOG mice may be suitable for the study of the pathogenesis of endometriosis.

Our findings raise the possibility that endothelial cells or their progenitors derived from human endometrium may have a unique angiogenic potential to migrate, invade, and form the vasculature in host tissue, even when originating from a different species. Bussolati *et al.* (28) have reported that tumor-derived endothelial cells, but not normal endothelial cells, possess a unique neoangiogenic ability to grow in immunodeficient mice and to form vascular structures linked with the mouse circulation. It therefore is conceivable that, in addition to the peritoneal environment (29), the




Fig. 5. Optical bioluminescence images and noninvasive quantitative assessment of the endometrial tissues reconstructed from lentivirally transduced SDECs in living NOG mice. (A) A bioluminescence image of the endometrial reconstructs expressing CBR luc in a ventrally positioned NOG mouse treated with E₂ alone. Bioluminescence images of the laparotomized mouse at the dorsal position (Lower Left) and its excised kidneys (Lower Right). (B–D) Representative BLI (Upper) and serial photon count measurements (Lower) of xenotransplanted OVX-NOG mice treated for different durations with the various indicated doses of E₂ pellets (B), with E₂ in combination with daily injections of ICI 182,780 (C), or with cyclic E₂ + P₄ treatment to induce artificial menstrual cycle-related changes (D) in accordance with a similar protocol as shown in Fig. 3C.

angiogenic potential of the endometrial endothelial cells per se may be one of the critical determinants for the establishment and development of the endometriotic lesion. Antiangiogenic therapy recently has been proposed as an alternative treatment for endometriosis (23, 30). This therapeutic strategy might be strengthened further by targeting endometrium- or endometriosis-specific angiogenesis, as postulated here.

The animal model described here has several advantages over the endometriosis models in current use. First, a single-cell suspension is adequate for several experimental procedures such as cell selection, genetic engineering, and quantitative assessment, as compared with the dissected sections of endometrial or endometriotic tissues used for the transplants in many endometriosis models (4). The use of SDECs also allows relatively easy production of several or even dozens of homogeneous mice, because only a small number of endometrial cells is required for the reconstruction of the endometrium. Second, the regenerated tissues exhibit abundant vascularization and the preservation of endometrial cell components and tissue organization, which enable the long-term maintenance of the reconstructed structure and the hormone-dependent changes characteristic of human cycling endometrium and/or endometriotic explants. Third, taking advantage of the lentivirus and CBR luc, whose emitted light has the capacity to pass through the thickened tissue, the transplants can be assessed for a prolonged period in a noninvasive, real-time, and quantitative manner.

Thus, it is demonstrated here that SDECs have the capacity for tissue regeneration and reconstruction. Combining this unique

potential together with NOG mice and lentivirus-mediated cell engineering, we report the unique animal model suitable for the study of endometrial physiology/pathophysiology and the pathogenesis of endometriosis through noninvasive, real-time, and quantitative assessment of ectopically reconstituted endometrium-like tissues. Furthermore, this animal model system can be potentially applicable for drug testing and gene-target validation not only in endometriosis but also in other various types of neoplastic disease when the relevant primary culture cells or cell lines are transplanted beneath the kidney capsule.

Materials and Methods

Detailed protocols can be found in *SI Methods*.

Tissue Collection. Proliferative phase endometrial specimens ($n = 20$) without any abnormalities or malignancies were collected from consenting women (aged 39–51 years) with normal menstrual cycles undergoing total abdominal hysterectomy for benign gynecological diseases. The use of these human specimens was approved by the Keio University Ethics Committee.

Preparation of SDECs. Human endometrial specimens were dissociated mechanically and enzymatically, filtrated, isolated by Ficoll gradient, and finally separated into endometrial stromal and glandular epithelial cell fractions as described previously (31, 32), with certain modifications. In brief, endometrial tissue samples were cut into small pieces and digested with 0.2% (wt/vol) collagenase (Wako, Osaka, Japan) and 0.05% DNase I

(GIBCO, Carlsbad, CA) in DMEM for 1.5 h at 37°C on a shaking rotor. The tissue digest was filtrated through a sterile 407- μ m mesh filter, followed by a 40- μ m cell strainer (BD Biosciences, Bedford, MA). The glandular fragments retained in the strainer were recovered by back-flushing.

Stromal cell suspension was layered over Ficoll-Paque PLUS (Amersham Biosciences, Piscataway, NJ) and centrifuged to remove red blood cells. The media/Ficoll interface layer mainly containing stromal and immune cells was aspirated and washed. Glandular fragments were digested with 0.05% trypsin-EDTA solution (Sigma-Aldrich, St. Louis, MO) and 0.05% DNase I by pipetting, washed, and filtrated through a 40- μ m cell strainer to yield a single-cell suspension. Mixtures of these two fractions were designated SDECs and were used as transplants or subjected to cell culture and lentiviral infection. Flow cytometric analysis revealed that the percentages (mean \pm SD) of CD9, CD13, CD31, and CD45 were $12.0 \pm 7.2\%$, $40.2 \pm 9.5\%$, $2.4 \pm 1.0\%$, and $46 \pm 13.0\%$ in SDECs, respectively. Procedures for preparing SDECs and the representative flow cytometric data are summarized schematically in SI Fig. 9.

Xenotransplantation and Hormonal Treatment. NOG mice (5) were used for xenotransplantation experiments. The single-cell suspension of SDECs (5×10^5) in 5–10 μ l of DMEM was injected underneath the kidney capsules (for details see *SI Methods*). At transplantation, NOG mice were OVX and implanted s.c. without (Fig. 1A, “no-Tx”) or with one or usually two E₂ pellets (Fig. 1A, “E₂”) (1.5 mg of E₂ per pellet; Innovative Research of America, Sarasota, FL). For P₄ or E₂ + P₄ treatment, 1 mg of P₄ was injected s.c. every day for the last 2 weeks (Fig. 1A). For cyclic E₂ + P₄ treatment, xenotransplanted OVX-NOG mice implanted with two E₂ pellets were subjected to two cycles of daily P₄ injections for 2 weeks with a 3-week interval (Figs. 3D and 5D). In some mice implanted with an E₂ pellet, 100 μ g per body weight per day of ICI 182,780 was injected s.c. every day from the first day of transplantation (Fig. 5C). These xenotransplanted mice were nephrectomized according to the experimental protocol (for details see *SI Methods*).

Histological and Immunofluorescence Analysis. Serial cryosections of the kidneys excised from the xenotransplanted NOG mice were air-dried, washed, and fixed. After permeabilization and

blocking, tissue sections were incubated with the pretitrated primary antibodies listed in SI Table 1. For indirect fluorescence staining, the first antibodies were visualized by incubation with secondary antibodies conjugated with Alexa Fluor 488 (green) or 568 (red) (Molecular Probes, Eugene, OR). Nuclei were stained with Hoechst 33258. Images were collected as described in *SI Methods*.

Infection of Lentivirus Expressing CBR luc and Preparation of Transduced SDECs. The gene fragment of CBR luc was excised from the pCBR-Basic vector (Promega, Madison, WI) and cloned into pCSII-EF-MCS-IRES2-Venus (33). Viral stock was produced as described in ref. 15. SDECs were cultured, infected with lentivirus, continuously propagated, harvested, and then dissociated into single cells. The PI-negative/Venus-positive SDECs were sorted by a MoFlo (Cytomation, Fort Collins, CO) and plated onto a culture dish or transplanted beneath the kidney capsule on the dorsal side in OVX-NOG mice.

BLI. We used a Xenogen-IVIS 100 cooled CCD optical macroscopic imaging system (SC BioScience Corporation, Tokyo, Japan) for BLI. For *in vitro* imaging, SDECs were plated at equal density and imaged in the presence of 150 μ g/ml D-luciferin (SC BioScience Corporation). For *in vivo* imaging, OVX-NOG mice xenotransplanted with lentivirally engineered SDECs were anesthetized and given an i.p. injection of D-luciferin (150 mg/kg body weight). All images were analyzed as described in *SI Methods*. To quantify the measured light, regions of interest (ROI) were defined over the transplanted area and all values were examined from an equal ROI.

We thank Tetsuro Tamaki for advice on xenotransplantation; members of the T.M. laboratory, members of the Kamakura Research Laboratories (Chugai Pharmaceutical Co., Ltd.), and Lawrence Y. Lein for technical assistance and helpful advice; and Shoka Kan, Kiyoshi Amemiya, and Yurie Yamamoto for collecting endometrial samples. This study was supported, in part, by grant-in-aids from the Japan Society for the Promotion of Science (to T.M. and to Y.Y.), a national grant-in-aid for the establishment of a high-tech research center in a private university (to T.M.), and a grant-in-aid from the 21st Century Center of Excellence program of the Ministry of Education, Science, and Culture of Japan at Keio University. H. Masuda is a recipient of research fellowships of the Japan Society for the Promotion of Science for Young Scientists.

- Smith SK (2001) *Trends Endocrinol Metab* 12:147–151.
- Donnez J, Smeets P, Gillerot S, Casanas-Roux F, Nisolle M (1998) *Hum Reprod* 13:1686–1690.
- Giudice LC, Kao LC (2004) *Lancet* 364:1789–1799.
- Grummer R (2006) *Hum Reprod Update* 12:641–649.
- Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et al. (2002) *Blood* 100:3175–3182.
- Fujiwara H, Tatsumi K, Kosaka K, Sato Y, Higuchi T, Yoshioka S, Maeda M, Fujii S (2003) *J Clin Endocrinol Metab* 88:3437–3443.
- Vince GS, Johnson PM (2000) *Biochem Soc Trans* 28:191–195.
- Kohnen G, Campbell S, Jeffers MD, Cameron IT (2000) *Hum Reprod* 15:284–292.
- Bird CC, Willis RA (1965) *J Pathol Bacteriol* 90:75–81.
- Dunn CL, Kelly RW, Critchley HO (2003) *Reprod Biomed Online* 7:151–161.
- Nisolle M, Donnez J (1997) *Fertil Steril* 68:585–596.
- Contag CH, Bachmann MH (2002) *Annu Rev Biomed Eng* 4:235–260.
- Wang X, Rosol M, Ge S, Peterson D, McNamara G, Pollack H, Kohn DB, Nelson MD, Crooks GM (2003) *Blood* 102:3478–3482.
- Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH (1999) *Proc Natl Acad Sci USA* 96:12044–12049.
- Okada S, Ishii K, Yamane J, Iwanami A, Ikegami T, Katoh H, Iwamoto Y, Nakamura M, Miyoshi H, Okano HJ, et al. (2005) *FASEB J* 19:1839–1841.
- Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A (2002) *Nat Biotechnol* 20:87–90.
- Zhao H, Doyle TC, Coquoz O, Kalish F, Rice BW, Contag CH (2005) *J Biomed Opt* 10:41210.
- Padykula HA (1991) *Ann NY Acad Sci* 622:47–56.
- Chan RW, Gargett CE (2006) *Stem Cells* 24:1529–1538.
- Nisolle M, Casanas-Roux F, Donnez J (2000) *Fertil Steril* 74:306–312.
- Grummer R, Schwarzer F, Bainczyk K, Hess-Stumpp H, Regidor PA, Schindler AE, Winterhager E (2001) *Hum Reprod* 16:1736–1743.
- Bruner-Tran KL, Webster-Clair D, Osteen KG (2002) *Ann NY Acad Sci* 955:328–339.
- Hull ML, Chamock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD, Fan TP, Smith SK (2003) *J Clin Endocrinol Metab* 88:2889–2899.
- Eggemont J, Donnez J, Casanas-Roux F, Scholtes H, Van Langendonck A (2005) *Fertil Steril* 84:492–499.
- Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G (1999) *Blood* 93:1612–1621.
- Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D (1991) *Nature* 349:329–331.
- Seli E, Arici A (2003) *Semin Reprod Med* 21:135–144.
- Bussolati B, Deambrosio I, Russo S, Deregis MC, Camussi G (2003) *FASEB J* 17:1159–1161.
- Gazvani R, Templeton A (2002) *Reproduction* 123:217–226.
- Dabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J (2002) *Am J Pathol* 161:909–918.
- Maruyama T, Yoshimura Y, Yodoi J, Sabe H (1999) *Endocrinology* 140:2632–2636.
- Sakai N, Maruyama T, Sakurai R, Masuda H, Yamamoto Y, Shimizu A, Kishi I, Asada H, Yamagoe S, Yoshimura Y (2003) *J Biol Chem* 278:16675–16682.
- Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) *J Virol* 72:8150–8157.

Nuclear Import of the Preintegration Complex Is Blocked upon Infection by Human Immunodeficiency Virus Type 1 in Mouse Cells[∇]

Naomi Tsurutani,^{1†} Jiro Yasuda,^{1,2} Naoki Yamamoto,³ Byung-II Choi,¹
Motohiko Kadoki,¹ and Yoichiro Iwakura^{1*}

Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo 108-8639,¹ Fifth Biology Section for Microbiology, Department of First Forensic Science, National Research Institute of Police Science, Kashiwa 277-0882,² and Department of Molecular Virology, School of Medicine, Tokyo Medical and Dental University, Tokyo 113-8510,³ Japan

Received 28 April 2006/Accepted 17 October 2006

Mouse cells do not support human immunodeficiency virus type 1 (HIV-1) replication because of host range barriers at steps including virus entry, transcription, RNA splicing, polyprotein processing, assembly, and release. The exact mechanisms for the suppression, however, are not completely understood. To elucidate further the barriers against HIV-1 replication in mouse cells, we analyzed the replication of the virus in lymphocytes from human CD4/CXCR4 transgenic mice. Although primary splenocytes and thymocytes allowed the entry and reverse transcription of HIV-1, the integration efficiency of the viral DNA was greatly reduced in these cells relative to human peripheral blood mononuclear cells, suggesting an additional block(s) before or at the point of host chromosome integration of the viral DNA. Preintegration processes were further analyzed using HIV-1 pseudotyped viruses. The reverse transcription step of HIV-1 pseudotyped with the envelope of murine leukemia virus or vesicular stomatitis virus glycoprotein was efficiently supported in both human and mouse cells, but nuclear import of the preintegration complex (PIC) of HIV-1 was blocked in mouse cells. We found that green fluorescent protein (GFP)-labeled HIV-1 integrase, which is known to be important in the nuclear localization of the PIC, could not be imported into the nucleus of mouse cells, in contrast to human cells. On the other hand, GFP-Vpr localized exclusively to the nuclei of both mouse and human cells. These observations suggest that, due to the dysfunction of integrase, the nuclear localization of PIC is suppressed in mouse cells.

A small animal model for AIDS would provide a valuable tool for the study of its pathogenesis and the evaluation of vaccine candidates and antiviral drugs. However, attempts to produce small animal models have been hampered thus far by species-specific host range barriers to infection by human immunodeficiency virus type 1 (HIV-1). CD4, the cellular receptor for HIV-1 (41, 49), was first identified as a host range barrier because mouse CD4 (muCD4) does not bind HIV-1 Env (46). Human CD4 (huCD4) transgenic (Tg) mice, however, were not susceptible to HIV-1 infection, suggesting the presence of additional barriers (47). Chemokine receptors were later identified as entry coreceptors (9, 22), but primary lymphocytes from mice transgenic for huCD4 and either huCXCR4 (70) or huCCR5 (13) exhibited little to no signs of productive infection.

Cyclin T1 (CycT1) is responsible for a transcriptional level barrier (3, 4, 26, 30, 58). CycT1 protein is a component of the TAK/pTEFb transcription factor complex (51, 78), and huCycT1 binds Tat and activates transcription from the promoter in the long terminal repeat (LTR). However, muCycT1 cannot

bind Tat. Nevertheless, introduction of the huCycT1 protein to rodent cells together with a mixture of human receptors was insufficient to induce productive viral infection (11, 52).

Additional barriers have been reported in the late steps of the viral life cycle (11, 27, 40, 42, 43, 53). These late-stage defects can be rescued by fusing HIV-1-infected rodent cells to uninfected human cells (11, 52), indicating that the defects are due to the lack of necessary factors in rodent cells rather than the presence of dominant inhibitors of HIV-1 replication. CRM1, a nuclear export factor that functions in association with Rev, and p32, a splicing inhibitor and Rev-binding protein, are suggested to be necessary late-phase factors (67, 83).

We previously produced Tg mice carrying the HIV-1 proviral genome in which the *pol* gene is deleted (HIV-Tg) (36). Although transgene expression in lymphoid tissues is barely detectable under normal physiological conditions, relatively high levels of p24 Gag protein were detected in the serum (up to 400 pg/ml) after injection of bacterial lipopolysaccharide (74). All mRNA species, including unspliced, singly spliced, and multiply spliced mRNAs were produced normally. Thus, once the viral genome is integrated into the host chromosome, viral genes are expressed at a reasonable efficiency even in mouse cells, suggesting that the major host range barriers are present in the early stage of infection (prior to viral DNA integration) rather than in the late stage. However, it is not yet known whether there are any additional host range barriers in the early steps.

* Corresponding author. Mailing address: Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81 3 5449 5536. Fax: 81 3 5449 5430. E-mail: iwakura@ims.u-tokyo.ac.jp.

† Present address: Laboratory of Viral Infection II, Kitasato Institute for Life Sciences, Kitasato University, Tokyo 108-8641, Japan.

[∇] Published ahead of print on 1 November 2006.

In this report, we investigated additional barrier steps of HIV-1 replication in mouse cells and found that the efficiency of viral genome integration into the host chromosome was low in huCD4/CXCR4 Tg mice. As this result suggested an additional barrier in the early steps of viral infection, we examined nuclear transport of the viral genome and demonstrated that integrase (IN)-dependent nuclear import of the preintegration complex (PIC) is blocked in mouse cells.

MATERIALS AND METHODS

Transgene construction. The huCD4 Tg vector (pCT4) was constructed as follows. The 0.85-kb XhoI-EcoRV fragment containing the muCD4 enhancer/promoter was ligated to a 1.8-kb EcoRV-HindIII fragment containing the huCD4 open reading frame, and then a 1.95-kb HindIII-SpeI fragment containing a rabbit β -globin intron sequence and a simian virus 40 (SV40) polyadenylation [poly(A)] signal was inserted into the HindIII-SpeI site downstream of the huCD4 gene (29) (Fig. 1A). To construct the huCXCR4 Tg vector, an XhoI-NotI fragment containing the entire coding region of huCXCR4 was isolated from pBCMGSNeo/HM89 (61), and the huCXCR4 fragment was blunted by T4 DNA polymerase, followed by insertion into the EcoRV site of pCDGH. pCDGH consisted of the muCD4 enhancer/promoter and a human growth hormone gene with its poly(A) signal but devoid of its initiation codon (pCFG) (80) (Fig. 1A). The XhoI-SpeI fragment from pCT4 and the XhoI-NotI fragment from pCFG were then purified and cojected into the male pronuclei of fertilized mouse eggs (C3H/HeN) (80). The transgenes were detected by dot blot hybridization using DNA prepared from mouse tails (34). Mice were kept under specific-pathogen-free conditions in an environmentally controlled clean room at the Center for Experimental Medicine, the Institute of Medical Science, the University of Tokyo. All equipment and supplies were sterilized, including the cages, water bottles, wood chips, and food pellets. All experiments were conducted according to the institutional ethical and safety guidelines for animal experiments and safety guidelines for gene manipulation experiments.

Northern blot hybridization. Northern blot analyses were carried out as previously described (80). The EcoRV-SpeI fragment of huCD4 and the XhoI-NotI fragment of huCXCR4 used for transgene construction were used as templates to make probes detecting huCD4 and huCXCR4 mRNA, respectively. The autoradiograms were developed, and the radioactivity of each band was quantified with a BAS 2000 Bio-Image analyzer (Fuji Film, Tokyo, Japan).

Plasmids. The HIV-1 pNL4-3 (X4-tropic, accession no. M19921) vector was obtained from A. Adachi (1). The HIV-1 pNL43luc Δ env vector, in which the *env* gene is defective and the *nef* gene is replaced by the firefly luciferase (*Luc*) gene, the pNL4-3 vector containing a mutation at the IN catalytic site (D116G), and an amphotropic Moloney murine leukemia virus (MuLV) envelope expression vector (pJD-1) were kindly provided by T. Masuda (54, 65, 76). A vesicular stomatitis virus G (VSV-G)-expressing plasmid (pMD-G) was obtained from L. Naldini (5, 62). The pGEM/NL-2-LTR plasmid was kindly provided by Y. Koyanagi (73).

The HIV-1 pNL43luc Δ env vector carrying a IN protein tagged with the SV40 nuclear localization signal (NLS) was constructed by using overlap extension PCR (33). First, two different PCRs were performed using HIV-1 pNL43luc Δ env vector as the template: one with the AflII-sense primer, 5'-CATCTTAAGACA GCAGTACAAATGGCAGTA-3', and NLS-antisense primer, 5'-GGCCTTTC TCTCITTTTTGGATCCTCATCTCTGCTACTTGCC-3', and the other with the NLS-sense primer, 5'-CCAAAAAAGAAGAGAAAGGCCTAACACATG GAAAAGATTAGT-3', and PflMI-antisense primer, 5'-CTCTTTTCTCCA TTCTATGGAGACTCCCTG-3'. These two PCR amplicons were then combined and used as the template for the third PCR with outer primers AflII-sense and PflMI-antisense. The final PCR product was digested with AflII and PflMI and ligated to the SpeI/AflII and SpeI/PflMI vector fragments of HIV-1 pNL43luc Δ env. The nucleotide sequence of the construct was confirmed by sequencing.

To prepare the expression vector for HIV-1 IN N-terminal fusion to enhanced green fluorescence protein (EGFP) (GFP-IN), the entire coding region of HIV-1 IN was amplified by PCR and inserted into the pEGFP-C2 expression vector (Clontech Laboratories, Palo Alto, CA) at its EcoRI and ApaI sites. The primers used to amplify the HIV IN were GFP-IN-sense, 5'-CCGGAATCCGGGCC ATAGCGCCTTTTATAGATGGAATAGAT-3', and GFP-IN-antisense, 5'-TC CGGGCCGGATTAATCCTCATCTGTCTACT-3'. To generate the expression vector for the HIV-1 Vpr N or C terminus fused to EGFP (GFP-Vpr. Vpr-GFP), the entire coding region of HIV-1 Vpr was amplified by PCR and




FIG. 1. (A) Transgene constructs. huCD4 or CXCR4 cDNA was placed downstream of the muCD4 enhancer/promoter and ligated to the SV40 poly(A) signal (huCD4) or to a defective human growth hormone gene containing the poly(A) signal (huCXCR4). (B) Transgene expression in lymphatic organs. Northern blot hybridization analysis was performed using 10 μ g of total RNA prepared from the thymus, spleen, or lymph nodes of WT or Tg mice. The positions expected for huCD4, huCXCR4, muCXCR4, and β -actin mRNA are indicated on the right.

inserted into the pEGFP-C2 or pEGFP-N1 expression vector at the HindIII and ApaI or HindIII and BamHI sites, respectively. The primers used to amplify HIV-1 Vpr were GFP-Vpr-sense, 5'-CCCAAGCTTGGGGACGCATGGA ACAAGCCCCAGAA-3', and GFP-Vpr-antisense, 5'-TCCGGGCCCGGACT AGGATCTACTGGCTCCATT-3', or Vpr-GFP-sense, 5'-CCCAAGCTTGGG GACATGGAACAAGCCCCAGAA-3', and Vpr-GFP-antisense, 5'-CGCGGA TCCGCGGAGGATCTACTGGCTCCATT-3', respectively. The amplified regions and the cloning junctions were confirmed by DNA sequencing.

Cell culture and isolation of human PBMCs and mouse splenocytes and thymocytes. Human fibroblast-like cell lines (293T and HeLa), a mouse embryo fibroblast-like cell line (NIH 3T3) derived from an NIH Swiss mouse (Fv-1⁰), and a mouse rectum carcinoma cell line (Colon-26) from a BALB/c mouse (Fv-1^b) were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS). The Colon-26 cell line was obtained provided from the Cell Resource Center for Biomedical Research Institute of Development, Aging, and Cancer, Tohoku University, Japan (75). Human T-cell lymphoma cell lines (MT-4 and Jurkat) and mouse T-cell lymphoma cell lines (EL4, YAC-1, and BW5147) were cultured in RPMI 1640 (SIGMA, Tokyo, Japan) containing 10% FBS. Human peripheral blood mononuclear cells (PBMCs) were obtained from peripheral blood. Briefly, buffy coats from the peripheral blood of healthy HIV-seronegative blood donors were separated over a Ficoll-Hypaque gradient (Ficoll-Paque PLUS; GE Healthcare Bio-Sciences, Tokyo, Japan). C3H/HeN mice (Charles River, Tokyo, Japan) were sacrificed at 8 weeks, and the splenocytes and thymocytes were isolated by passage through nylon mesh. Human PBMC suspensions and mouse splenocytes

and thymocytes were stimulated with 1% phytohemagglutinin (SIGMA, Tokyo, Japan). These cells were grown in RPMI 1640 medium containing 4 ng/ml of recombinant human interleukin 2 or mouse interleukin 2 (Peprotech EC Ltd, London, United Kingdom) per ml and 10% FBS. After 1 week, human PBMCs and mouse splenocytes and thymocytes were >96% T cells and >40% activated cells, as judged by fluorescence-activated cell sorter analysis using anti-CD3 or anti-CD69 monoclonal antibodies (BD Biosciences, Tokyo, Japan), respectively (data not shown).

Virus preparation and infection assays. HIV-1 strain NL4-3 was propagated in MT-4 cells, and the supernatants were filtered and stored at -80°C until use. For single-round infection assays, pseudotyped viruses were generated by cotransfection of 293T cells with pNL43luc Δ env vector and an amphotropic Moloney MuLV envelope expression vector (pJD-1) or a VSV-G envelope expression vector (pMD-G) using Lipofectamine PLUS (Invitrogen) (76). The pNL43luc Δ env vector containing a mutation at the IN catalytic site (D116G) was used as a control (54). The culture supernatants of the transfected 293T cells were harvested at 48 h posttransfection, filtered through 0.45- μm filters, and used as the virus preparations. Each virus preparation was treated with DNase I (40 $\mu\text{g}/\text{ml}$; Worthington Biochemical Co., Lakewood, NJ) in the presence of 10 mM MgCl_2 at 37°C for 1 h to avoid DNA contamination. An aliquot of each virus preparation was incubated at 65°C for 1 h and used as a heat-inactivated control. To monitor viral gene expression from the pNL43luc Δ env vector carrying a IN protein tagged with the SV40 NLS, luciferase activity in transfected 293T cells was measured on a Lumat LB9507 luminometer (BERTHOLD, Technologies, Bad Wildbad, Germany). At 48 h posttransfection, 293T cells were lysed with 1 ml of luciferase lysis buffer (Promega). One microliter of each cell lysate was subjected to the luciferase assay. Human PBMCs (5×10^6) or HeLa (5×10^5), MT-4 (5×10^6), Jurkat (5×10^6), mouse splenocytes (5×10^6), mouse thymocytes (5×10^6), NIH 3T3 (5×10^5), BW5147 (5×10^6), EL4 (5×10^6), or YAC-1 (5×10^6) cells were infected with an aliquot (2 ml; containing approximately 500 ng [NL4-3], 200 ng [HIV-1/MuLV], or 50 ng [HIV-1/VSV-G] of p24) of DNase-treated virus. The infection proceeded in the presence of Polybrene (SIGMA, Tokyo, Japan) (10 $\mu\text{g}/\text{ml}$) at 37°C . After 6 h, the viruses were removed, and the cells were overlaid with fresh media and incubated at 37°C . For p24 CA analysis, the infected cell supernatants were removed on the indicated days following infection. The levels of HIV-1 p24 antigen were determined by an enzyme immunoassay system (RETRO-TEK; ZeptoMatrix Corp., Buffalo, NY). For luciferase analysis, infected cells were harvested 4 days after infection, and the total cell pellets from each well were washed twice with phosphate-buffered saline (PBS) and lysed in luciferase lysis buffer (Promega). Luciferase activity (measured in a relative light units [RLU]) was measured on a Lumat LB9507 luminometer (BERTHOLD, Technologies, Bad Wildbad, Germany).

Analysis of HIV-1 DNA synthesis and formation of 2-LTR circles. Cells were harvested 24 h after infection. After washing with PBS, nucleic acids were extracted as described previously (81). Briefly, cells were disrupted in urea lysis buffer (4.7 M urea, 1.3% sodium dodecyl sulfate [SDS], 0.23 M NaCl, 0.67 mM EDTA, and 6.7 mM Tris-HCl [pH 8.0]), phenol-chloroform extracted, and ethanol precipitated. The DNA pellet was resuspended in distilled H_2O , and an aliquot of each sample was analyzed by PCR. For *ex vivo* infection of primary lymphocytes from huCD4/CXCR4 Tg mice, partial reverse transcripts of the viral DNA were quantified by semiquantitative PCR. The primers used were as follows (37, 45, 81): R-U5, R, 5'-GCCTCAATAAAGCTTGCCTTG-3' (sense, positions 522 to 542); U5, 5'-CCACTGCTAGAGATTTCCAC-3' (antisense, positions 616 to 638); Gag forward, 5'-TGGGGGGACATCAAGCAGCCATG CA-3' (sense, positions 1360 to 1385); Gag reverse, 5'-CTATGCACTTCCCTTGGTTCTCT-3' (antisense, positions 1474 to 1498). The PCR program was 30 cycles at 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min in the presence of [^{32}P]dCTP. The PCR products were electrophoresed on an 8% polyacrylamide-Tris-borate-EDTA gel. The autoradiograms were developed, and the radioactivity of each band was quantified by a BAS 2000 Bio-Image analyzer. For single-round infections, the DNA was measured by quantitative PCR using an ABI PRISM 7900HT qPCR machine (Applied Biosystems, Tokyo, Japan). The PCR primer pairs were as follows: R-U5 (M667/AA55), R-gag (M667/M661) (76), and the 2-LTR junction's sequence (2-LTR-S/2-LTR-AS) (73). The cycling conditions included a hot start (50°C for 2 min, 95°C for 10 min), followed by 40 cycles of denaturation (95°C for 15 s) and extension (60°C for 1 min). To compensate for varying DNA sample recovery, the data are presented as ratios of HIV-1 DNA to β -actin DNA.

Cassette ligation-mediated PCR and integration analysis. For the detection of the HIV-1 integration form, we designed a cassette ligation-mediated PCR system using an *in vitro* LA cloning kit (TaKaRa BIO, Shiga, Japan) (35) (see Fig. 3A). Briefly, 5 μg of DNA was digested with EcoRI and ligated to double-stranded DNA cassettes with compatible ends. The cassette-ligated restriction

fragments were then subjected to two rounds of PCR using the cassette- and HIV-specific primers C1 (5'-GTACATATTGTCGTTAGAACGCGTAATACG ACTCA-3') and Gag reverse (described above) for the cassette, gag, and its upstream region and C2 (5'-CGTTAGAACGCGTAATACGACTCACTATAG GGAGA-3') and U5 reverse (described above) for the cassette sequence downstream of C1 and the LTR region. PCR was performed according to the manufacturer's instructions. The amplification conditions were 30 cycles of 1 min at 94°C , 2 min at 54°C , 2 min at 72°C , and a final extension of 1 min at 72°C . The amplified products were resolved on 2% agarose gels and stained with SYBR green (FMC Bioproduct, Rockland, ME).

Fluorescence microscopy. HeLa (4×10^4), NIH 3T3 (3×10^4), and Colon-26 (3×10^4) cells were seeded onto 8-well culture slides (Nalge Nunc International, Rochester, NY) and transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen). At 24 h posttransfection, the cells were washed once in PBS and fixed with acetone for 5 min. After washing with PBS, the cells were mounted in 90% glycerol-50 mM NaHCO_3 - Na_2CO_3 and covered by a coverslip. Confocal microscopy was performed with a Nikon Optiphot-2 fluorescence microscope with a Bio-Rad MRC 1024 laser confocal imaging system, and the digital images were prepared using Adobe Photoshop software.

Particle preparation and Western blot analysis. The culture supernatant (5 ml) of HIV-1 producing plasmid-transfected 293T cells was collected at 48 h postinfection. It was centrifuged through 20% (wt/vol) sucrose-PBS in an SW55 rotor (Beckman Coulter) at 4°C at $147,000 \times g$ for 2 h (56), and the pellet was resuspended in PBS. The viral pellets were hearted at 90°C for 10 min in the presence of sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, 0.005% bromophenol blue). Then viral proteins were electrophoresed on a 12% SDS-polyacrylamide gel containing 0.2% SDS. Following blotting of proteins onto a polyvinylidene difluoride membrane, the membrane was first incubated with an antiserum from an AIDS patient (provided by Y. Inagaki, Tokyo Medical and Dental University, Tokyo, Japan, and Y. Koyanagi, Kyoto University, Kyoto, Japan), followed by horseradish peroxidase-conjugated anti-human immunoglobulin. HIV-1 proteins were visualized using an enhanced chemiluminescence detection system (GE Healthcare Bio-Science, Tokyo, Japan).

Statistical analysis. Data were analyzed using Excel and Student's *t* test. A *P* value of <0.05 was considered statistically significant, and all results are presented as means \pm standard errors of the means (SEM).

RESULTS

Lymphocytes from huCD4/CXCR4 Tg mice do not fully support HIV-1 infection. To elucidate the host range barriers of HIV-1 replication in mice, we analyzed the early processes of HIV-1 infection in huCD4/CXCR4 Tg mouse splenocytes. Transgenic mice were generated by introducing both huCD4 and huCXCR4 cDNA along with the muCD4 enhancer/promoter into fertilized C3H mouse eggs (Fig. 1A). As shown in Fig. 1B, the huCD4 and huCXCR4 mRNAs were detected mostly in the thymus but also in the lymph nodes and spleen. Two huCD4 mRNA species were detected due to alternative splicing of the SV40 gene that was ligated to the huCD4 gene (Fig. 1B). fluorescence-activated cell sorter analyses showed that Tg splenocytes and thymocytes both expressed huCD4 and huCXCR4 on their cell surfaces (data not shown).

To examine the susceptibility of these Tg mice to HIV infection, splenocytes and thymocytes were isolated from the mice and infected with T-tropic HIV-1 (NL4-3) or M-tropic HIV-1 (JR-CSF). However, we could not detect any p24 antigen in the culture supernatant of these Tg mouse-derived cells, although significant levels of p24 (up to 80 pg/ml) were produced in human PBMC culture supernatant 12 days after infection.

To determine the process by which the viral replication is blocked, we analyzed the early infection steps by examining the viral genomic structure. Twenty-four hours after HIV-1 infection of the huCD4/CXCR4 Tg splenocytes, cells were har-




FIG. 2. HIV infection of splenocytes and thymocytes of WT and huCD4/CXCR4 Tg mice. Splenocytes or thymocytes from WT mice, Tg mice, or human PBMCs were isolated and infected with equivalent amounts of DNase-treated NL4-3 virus at 37°C for 6 h. After 6 h, the viruses were removed and the cells were treated with trypsin (500 μ g/ml) at 37°C for 10 min and then washed in growth medium. (A and B) Splenocytes were harvested at 24 h postinfection. Total DNA was extracted from the cells and subjected to PCR analysis with a primer pair for R/U5 (A) or R/gag (B). The reaction was carried out using the DNA preparation from 1×10^5 cells ($\times 1$) or 1×10^4 cells ($\times 10^{-1}$). In panel B, the lanes marked 5×10^2 and 5×10^3 represent PCR products using 5×10^2 or 5×10^3 copies of the pNL4-3 plasmid as the template.

vested and total DNA was extracted. Early (R-U5) and late-infectious intermediate products (R-gag) were determined using semiquantitative PCR with specific primers. As shown in Fig. 2A and B, both infectious intermediates were detected specifically in the DNA isolated from the splenocytes of huCD4/CXCR4 Tg mice exposed to HIV-1, indicating that viral entry and reverse transcription had proceeded normally in mouse cells provided that human viral receptors were supplied. Similar results were also obtained in huCD4/CCR5 Tg mouse splenocytes infected with HIV-1 JR-CSF (data not shown). In contrast, the early infectious intermediate was not detected in wild-type mouse splenocytes, indicating a block upon viral entry. Taken together, these results suggest that HIV-1 replication in huCD4/CXCR4 Tg splenocytes was blocked later than the reverse transcription step(s).

HIV-1 infection of mouse cells is blocked at steps preceding integration into the host chromosome. We next examined the integration of the HIV-1 genome into the host chromosome. The pNL4-3 vector containing a mutation at the IN catalytic site (D116G) was used as a control (54). DNA from the infected cells was digested with EcoRI, which cut proviral DNA at only one site (nucleotide number 5743 of NL4-3, accession no. M19921). The DNA was then ligated to an EcoRI-specific cassette and subjected to the first round of PCR using primers specific for the cassette and the *gag* region, followed by the second round of PCR using primers for the cassette and the LTR region (Fig. 3A). As a result, the integrated viral DNA was visualized as smearing bands greater than 638 bp, which is




FIG. 3. Suppression of NL4-3 virus DNA integration in the mouse chromosome. Human PBMCs and murine splenocytes were infected with equivalent doses of DNase-treated NL4-3 virus. After 6 h, the virus was removed and the cells were washed with growth medium. At 1 day postinfection, the cells were harvested and used to extract total DNA. The DNA (5 μ g) was digested with EcoRI and ligated to double-stranded DNA cassettes with compatible ends. The cassette-ligated DNA fragments were used as templates for nested PCR using cassette- and HIV-specific primers. (A) Schematic representation of cassette ligation-mediated PCR and the primers used to detect HIV integration into the host chromosome. (B and C) Detection of the chromosome-integrated forms of viral DNA. (B) Human PBMC preparations from two donors (A and B) were infected with NL4-3-WT or integrase mutant (D116G), and the DNAs were subjected to PCR analysis. Markers: 23.1, 9.4, 6.6, 4.3, 2.3, 2.0, and 0.564 kb (λ /HindIII). (C) DNA was isolated from NL4-3-infected splenocytes or thymocytes from WT or Tg mice or human PBMCs following infection and subjected to PCR analysis. Note the smearing bands in virus-infected human PBMCs but not in huCD4/CXCR4 Tg mice. Marker: λ /HindIII.

the original length between C2 and U5 reverse primers without insertion. Smearing bands were clearly detected when the DNA from HIV-1 wild type (WT)-infected human PBMCs was analyzed. In contrast, no smearing bands were detected with the DNA from HIV-1-D116G infected human PBMC, HIV-1-WT infected splenocytes from WT, and huCD4/CXCR4 transgenic mice (Fig. 3B and C). These results suggest that HIV-1 replication is also blocked in mouse cells at steps between the entry and viral DNA integration steps or at the viral integration step in addition to the adhesion/entry step.

The infection of mouse cells with both HIV-1/pJD-1 and HIV-1/VSV-G pseudotyped virus are blocked at a postentry step. To examine the possibility that HIV-1 replication in mouse cells is blocked at steps between the viral entry and DNA integration steps, we analyzed the early steps of viral infection using HIV-1 pseudotyped viruses in which the Env is replaced by an amphotropic MuLV Env (HIV-1/pJD-1) or by the G protein of VSV (HIV-1/VSV-G) and the *nef* gene is replaced by the firefly luciferase gene (76). The MuLV envelope pseudotype uses a ubiquitously expressed phosphate transporter as the receptor (55), and the VSV-G envelope pseudotype is capable of infecting cells through a carbohydrate receptor and the endocytic pathway (2). By using these pseudotyped viruses, we overcame the barriers at the adhesion and entry steps.

Among the adherent cells tested, 293T and HeLa cells showed high luciferase activity upon infection with both types of pseudotyped viruses, whereas NIH 3T3 cells yielded 10- to 100-fold-lower signals (Fig. 4). Similarly, the mouse T-cell lines BW5147, EL4, and YAC-1 displayed 100- to 1,000-fold-lower signals than did the human T-cell lines MT4 and Jurkat. Furthermore, luciferase expression efficiency was lower, by more than 1,000-fold, in mouse primary splenocytes than in human PBMCs. The relative sensitivity to infection of these cells was similar between the two pseudotyped viruses, although the efficiency of infection was approximately 10-fold higher in the HIV-1/VSV-G infection. Thus, these results again support a species-specific block in mouse cells subsequent to the entry step.

Reverse transcription of HIV-1 proceeds normally in mouse cells. We next evaluated the ability of mouse cells to support HIV-1 DNA synthesis. One day after infection, total DNA was harvested from various infected cells and subjected to quantitative PCR analyses. Both early (R-U5) and late (R-gag) reverse transcription products were specifically detected in DNA isolated from human and mouse cells exposed to both of the pseudotyped viruses, HIV-1/pJD-1 (Fig. 5A) and HIV-1/VSV-G (Fig. 5B). No R-U5 or R-gag products were detected when heat-inactivated (65°C, 1 h) viruses were infected, indicating that these products were not derived from the transfected HIV-1 DNA carryover. The copy number of R-U5, which reflects the efficiency of viral entry, was higher in mouse cells (NIH 3T3, BW5147, and splenocytes) than in human cells (HeLa, MT4, and PBMCs). The ratio of R-gag/R-U5 was calculated to evaluate the efficiency of the reverse transcription because R-U5 reflects the efficiency of entry (Fig. 5A and B, lower panels). No significant difference in the efficiency of reverse transcription was observed between mouse cells and human cells exposed to HIV-1/pJD-1 (Fig. 5A) and HIV-1/VSV-G (Fig. 5B). These results indicated that mouse cells




FIG. 4. Analysis of HIV-1 pseudotype virus replication in mouse cells. Human and murine cells were infected with equivalent doses of pNL43luc Δ env that was pseudotyped with either MuLV (A) or VSV-G (B) at 37°C for 6 h. After removal of the virus, cells were washed in growth medium. Luciferase activity was measured at 4 days postinfection, and normalized activities relative to the total protein quantity are shown. The data represent the means \pm SEM of results from three wells. The data were reproduced in three independent experiments.

supported reverse transcription at an efficiency similar to that of human cells.

Nuclear import of the PIC is blocked in mouse cells. After completion of reverse transcription, the PIC crosses the




FIG. 5. The efficiency of the reverse transcription of HIV-1 in mouse cells. Human and murine cells were infected with equivalent doses of DNase-treated WT or integrase mutant (D116G) MuLV pseudotyped virus (A) or VSV-G pseudotyped virus (B). At 1 day postinfection, the cells were harvested, and the total DNA was extracted and subjected to quantitative real-time PCR analysis using primer pairs for R/U5 (upper panels) or R/gag (middle panels). The copy numbers of HIV-1 DNA per 1 μ g β -actin are shown. The reverse transcription (RT) efficiency is calculated by dividing the late RT product (R-gag) by the early RT product (R-U5) (lower panel). The data represent the means \pm SEM of results from three wells. The data were reproduced in three independent experiments.

nuclear membrane and enters the nucleus. Ligases within the nucleus then circularize the proviral DNA (2-LTR containing circular DNA) before its integration into the host chromosome (17, 57, 82). Although these 2-LTR circles are nonfunctional, they can serve as a measure of viral nuclear

entry. To assess the efficiency of PIC transport into the nuclei of mouse cells, we estimated de novo-synthesized 2-LTR circular-form DNA by PCR using primer pairs that amplify sequences unique to this DNA form. The fragment corresponding to the 2-LTR circular junction was clearly




FIG. 6. Suppression of the 2-LTR circular form of DNA in mouse cells. Human and mouse cells were infected with equivalent doses of DNase-treated WT or integrase-mutant (D116G) MuLV pseudotype virus (A) or VSV-G pseudotype virus (B). The DNA from the infected cells was subjected to quantitative real-time PCR analysis using a primer pair specific for the 2-LTR circular form of the DNA (upper panels). The nuclear import efficiency was calculated by dividing the 2-LTR products by the late reverse transcription products (lower panels). The data represent the means \pm SEM of results from three wells, and the data were reproduced in three independent experiments. *, $P < 0.05$; **, $P < 0.01$ (determined by Student's t test).

detected at 1 day postinfection in the DNA samples from HeLa, NIH 3T3, MT-4, BW5147, and human PBMCs infected with HIV-1/pJD-1 pseudotyped virus (Fig. 6A, upper panel). However, only a small amount of 2-LTR circle was detected in the mouse splenocytes. A similar tendency was observed in cells infected with the HIV-1/VSV-G pseudotyped virus (Fig. 6B, upper panel). The 2-LTR DNA in mouse cells was also measured at 2 and 4 days postinfection using both pseudotyped viruses and provided similar results (data not shown).

The ratio of 2-LTR/R-gag was calculated to evaluate the efficiency of nuclear import because the copy number of 2-LTR in the nucleus should be dependent on the amount of cytoplasmic R-gag, which represents the precursor of 2-LTR. The efficiency was very low and not significantly different between human and mouse when wild-type HIV-1 pseudovirus was infected (Fig. 6, lower panel). Because the nuclear concentration of 2-LTR is determined by the balance between accumulation of PIC by nuclear import and loss of PIC from the nucleoplasm by chromosome integration, we next used an integration-defective mutant, D116G, to examine only

the efficiency of nuclear import. As shown in Fig. 6, the ratio was significantly lower in NIH 3T3 cells than in HeLa cells (33% or 43% of HeLa cells) and in BW5147 cells than in MT4 cells (12% or 17% of MT4 cells) when they were infected with HIV-1/pJD-1 or HIV-1/VSV-G, respectively (Fig. 6A and B, lower panels). We were unable to compare the efficiency of PIC import in human PBMCs and mouse splenocytes because the 2-LTR circle was not detected in mouse splenocytes. These results suggested that the nuclear import of the PIC is blocked in mouse cells, especially in splenocytes.

A block in the nuclear localization of the PIC is caused by a defect in IN nuclear localization. As Vpr and IN play important roles in importing the PIC into the nucleus, we hypothesized that Vpr and/or IN is nonfunctional in mouse cells due to the inability to utilize the cellular factors necessary for trafficking to the nucleus. To directly examine the karyophilic properties of HIV-1 IN in mouse cells, we generated an expression vector with HIV-1 IN in which the N terminus was fused to EGFP (GFP-IN). Since it was reported that β -galactosidase fusion to the C terminus of IN could not be located in




FIG. 7. Inhibition of IN-dependent GFP nuclear import in mouse cells. HeLa (A, D, G, and J), NIH 3T3 (B, E, H, and K), and Colon-26 cells (C, F, I, and L) were transfected with plasmids expressing GFP only (A, B, and C), GFP fused to the HIV-1 Vpr N terminus (GFP-Vpr) (D, E, and F), GFP fused to the HIV-1 Vpr C terminus (Vpr-GFP) (G, H, and I), and GFP fused to HIV-1 IN (J, K, and L) using Lipofectamine 2000. At 24 h posttransfection, the cells were fixed and visualized by confocal fluorescence microscopy. Note that the nuclear localization of GFP-IN is inhibited in mouse cells (K and L).

the nucleus (44), we did not examine the C terminus fusion construct (IN-GFP). We also generated HIV-1 Vpr expression vectors in which the N or C terminus was fused to EGFP (GFP-Vpr and Vpr-GFP, respectively). At 24 h postinfection, HeLa, NIH 3T3, and Colon-26 cells were transfected with the GFP fusion vectors, and the subcellular localization of IN or Vpr was examined with a confocal microscope. We used Colon-26 cells (Fv-1^a) in addition to NIH 3T3 cells (Fv-1^b) because Fv-1 may exert its antiretroviral effect at a postentry step, after reverse transcription and prior to integration (38, 79). Colon-26 cells and NIH 3T3 cells showed similar levels of luciferase activity upon infection with both types of pseudotyped viruses. Control GFP without IN or Vpr was distributed uniformly throughout both the cytoplasm and the nuclei in all cells examined (Fig. 7A to C). GFP-Vpr, on the other hand, accumulated almost exclusively in the nuclei of HeLa (Fig. 7D), NIH 3T3 (Fig. 7E), and Colon-26 (Fig. 7F) cells, although low levels of nuclear membrane association were also observed in NIH 3T3 cells (Fig. 7E). Vpr-GFP also accumulated almost exclusively in the nuclei of HeLa (Fig. 7G), NIH 3T3 (Fig. 7H), and Colon-26 (Fig. 7I) cells. These results indicated that HIV-1 Vpr has strong karyophilic properties and that, even in mouse cells, it can be transported across the nuclear membrane. In contrast, although GFP-IN accumulated almost

exclusively in the nuclei of HeLa cells (Fig. 7J), GFP-IN was localized only in the cytoplasm of NIH 3T3 (Fig. 7K) and Colon-26 (Fig. 7L) cells. Thus, our results demonstrate that IN-mediated nuclear transport of HIV-1 PIC is impaired in mouse cells of both Fv-1 genotypes.

Addition of the SV40 NLS to the C terminus of HIV-1 integrase enhances viral infectivity in mouse cells. To analyze the role of IN in nuclear localization of HIV-1, we constructed an HIV-1 pNL43lucΔenv vector with the SV40 NLS at the C terminus of IN (IN-NLS), and pseudotyped virus was generated by cotransfection of 293T cells with the pNL43lucΔenv wild type or IN-NLS vector and VSV-G expression vector. Luciferase activity in the cell lysate of 293T cells transfected with IN-NLS was increased 2.5-fold compared to that transfected with wild-type virus (Fig. 8A). To verify that the gag-pol polyprotein processing was completed in IN-NLS virus particles, we performed Western blot analysis using an AIDS patient serum. No difference of the viral components was observed between parental WT and IN-NLS viruses (Fig. 8B). The content of p24 protein of the IN-NLS was also shown to be normal using a specific monoclonal antibody (data not shown). These results showed that addition of NLS to IN significantly activates viral replication.

Then we tested the susceptibility of HeLa, NIH 3T3, BW5147, and MT4 cells to IN-NLS infection. Addition of the




FIG. 8. Enhancement of viral infectivity to mouse cells by the addition of SV40 NLS to the C terminus of IN. (A) Luciferase activity in an HIV-1 pNL43luc Δ env vector (WT) or pNL43luc Δ env vector carrying an SV40 NLS-ligated IN (IN-NLS)-transfected 293T cells were measured at 2 days posttransfection. The data were reproduced in 10 independent experiments. (B) Virus particles were collected at 48 h posttransfection and resuspended in PBS. The viral pellets were heated at 90°C for 10 min in the presence of sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, 0.005% bromophenol blue). Then viral proteins were electrophoresed on a 12% SDS-polyacrylamide gel. Viral proteins were detected with AIDS patient serum. Positions of the major viral proteins are indicated together with molecular weight markers. (C) Human and mouse cells were infected with equivalent amounts of WT (\square) or IN-NLS (\blacksquare) virus at 37°C for 6 h, and then the virus was removed. The luciferase activity was measured 4 days after infection, and the activity was normalized relative to the total amount of protein. Means \pm SEM are shown. (D) Relative Luc activities of IN-NLS virus-infected cells compared to WT virus-infected cells were calculated using the data shown in panel C. Means \pm SEM are shown. (E) NIH 3T3 cells transfected with a plasmid expressing GFP, GFP-IN, or GFP-IN-NLS fusion protein were analyzed by confocal microscopy. At 24 h posttransfection, cells were fixed and GFP was detected by a confocal fluorescent microscope. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ (by Student's t test).

SV40 NLS to the C terminus of IN significantly enhanced viral infectivity in all cell lines used (Fig. 8C). As the NLS fusion at the C terminus of IN disrupted the *vif* gene, we did not analyze the infectivity to human PBMC, which was nonpermissive to *vif*-deficient virus (24, 69). Interestingly, the effect of the NLS on viral infection was significantly stronger in mouse cells than in human cells (Fig. 8D).

We also analyzed the karyophilic property of GFP-IN-NLS in which EGFP was fused to the N terminus and the SV40 NLS at the C terminus of IN. GFP-IN-NLS accumulated almost exclusively in the nucleus of NIH 3T3 cells, in contrast to GFP-IN (Fig. 8E). These results indicate that the addition of functional NLS to IN compensates the functional defects of IN in mouse cells.

DISCUSSION

HIV-1 replication in rodent cells is blocked at multiple steps, including viral entry, transcription, nuclear export of the mRNA, assembly, and budding (77). In this study, we demonstrated that an additional host range barrier is present in mouse cells at the PIC nuclear transport step. We suggest that this restriction is caused by the dysfunction of the HIV-1 IN-dependent PIC import system.

We found that the ratio of the 2-LTR circular product to the late reverse transcription product (R-gag), which are produced in the nucleus and cytoplasm, respectively, was decreased in mouse splenocytes relative to human PBMCs after infection with both HIV-1/MuLV and HIV-1/VSV-G pseudotyped vi-

ruses (Fig. 6, lower panels). This indicates a reduction in nuclear import of the PIC. The efficiency of nuclear transfer of the viral PIC was recently reported to be reduced in mouse T cells relative to human T cell lines, but not in NIH 3T3 cells (7). These results are consistent with ours, although we cannot explain their lack of reduction in the NIH 3T3 cells. Our system using the IN mutant virus is probably more sensitive in detecting the defect.

We showed that the infection efficiency, as determined by luciferase activity, was 10 to 100, 100 to 1,000, and >1,000 times lower than in human cells in mouse adherent cells, T cell lines, and primary cells, respectively (Fig. 4). As the PIC nuclear import reduction in mouse cells was at most 60 to 90% compared to human cells (Fig. 6), it is clear that other barriers are also involved in the HIV-1 replication restriction in mouse cells. In this regard, we showed that the 2-LTR/R-gag ratio following infection with WT HIV-1 was similar between HeLa and NIH 3T3 cells and between MT4 and BW5147 cells, in contrast to our observations with the IN-deficient mutant virus (Fig. 6, lower panels). These results are explainable if the R-gag products integrate rapidly into the host chromosome in human cells compared to mouse cells, assuming that a constant proportion of free R-gag products is converted into the 2-LTR form. Thus, integration of the R-gag products into the host chromosome may also be inhibited in mouse cells. In accordance with this idea, we demonstrated that the integration frequency of HIV-1 was greatly reduced upon infection with WT HIV-1 in mouse cells transgenic for the huCD4/CXCR4 genes.

There are two formal explanations for the inability of the mouse cells to support HIV-1 PIC nuclear import. One is the absence of a required human-specific factor, and the other is the presence of an inhibitory factor(s) in mouse cells. However, because mouse-human cell fusions allow viral replication, mouse cells most likely do not have such an inhibitory factor and are rather devoid of a critical factor for the import of the HIV-1 PIC (52).

Although the mechanisms of PIC nuclear import have not been elucidated completely, NLSs are present in three viral proteins (MA, Vpr, and IN) as well as in a central DNA flap produced during reverse transcription that also contributes to the successful nuclear targeting of the PIC (59, 64, 71). Although their respective contributions remain controversial and unclear, it has been clearly shown that both Vpr and IN are karyophilic and rapidly accumulate in the nuclei of infected cells (6, 16, 19, 20, 25, 32, 48, 63, 66, 68). Meanwhile, localization of MA to the nucleus is not well established (14, 23). In this report, we demonstrated that GFP-fused IN remained in the cytoplasm of NIH 3T3 cells, in contrast to its accumulation in the nuclei of HeLa cells. On the other hand, when GFP-fused Vprs were examined, they localized to the nuclei of both NIH 3T3 and HeLa cells. The nuclear distribution of GFP-IN, but not GFP-fused Vpr, was also inhibited in the Colon-26 mouse cell line. These observations indicate that Vpr can be imported into the nucleus using separate pathways. IN, on the other hand, cannot be imported efficiently into the nuclei of mouse cells, and this is probably due to the inability of IN to interact with mouse nuclear import system.

In support for this notion, we showed that nuclear import of IN was much more enhanced in mouse cells than in human

cells when authentic SV40 NLS was added to IN (Fig. 8). Furthermore, the addition of this NLS to IN significantly enhanced the infectivity of HIV-1 pseudovirus to mouse cells. These results indicate that endogenous nuclear localization signals of IN are not fully functional in mouse cells.

In this context, it is known that the NLSs within HIV-1 IN are composed of basic amino acid-rich sequences that interact with importin β through the adapter importin (25). We previously showed, however, that mutational disruption of the suggested NLSs could not abolish the nuclear localization of a GFP-IN fusion protein (76). Recent studies have shown that nonclassical NLSs are necessary and sufficient to locate the viral PIC into the nuclei (12). Depienne et al. suggested that the *in vitro* nuclear import of IN does not require known cytosolic transport factors, including karyopherin β family proteins (18). Two proteins have recently been reported to mediate PIC import. The first is lens epithelium-derived growth factor (LEDGF/p75), a protein implicated in the regulation of gene expression and cellular stress responses. LEDGF interacts with HIV-1 IN *in vitro* and in living cells (50) and colocalizes with HIV-IN in the nuclei of human cells (15). The second is importin 7, a mildly hydrophobic protein belonging to the importin β superfamily. This protein is suggested to interact with basic proteins, such as IN, that bind viral nucleic acids (21). It is currently unclear which protein(s) is important in these processes and defective in mouse cells. Clearly, further work is necessary to identify the host cell factors that are associated with IN in human cells and defective in mouse cells.

Thus far, several host restriction factors are known to be involved in the suppression of HIV-1 replication in the early phase of its life cycle in mouse cells. Friend virus susceptibility factor-1 (Fv-1) is involved in the restriction of specific mouse cell genotypes to MuLV (10, 28). The Fv-1 targets the MuLV capsid and stops the nuclear import of the PIC (8, 39). However, recent reports have noted that there is no correlation between HIV-1 susceptibility and cellular Fv-1 genotype (7, 31). Tripartite motif 5 α (TRIM5 α), encoded by the gene *Lv-1*, is another restriction factor (72). TRIM5 α inhibits viral replication in rhesus macaque cells at a step after entry but before the reverse transcription of HIV-1 by targeting the viral capsid protein (60). Thus, both Fv-1 and TRIM5 α function in processes other than the transport of PIC into the nucleus.

In conclusion, we have demonstrated that PIC nuclear import is blocked in mouse cells and that dysfunctional IN is at least partially responsible for the barrier. Further characterization and identification of factors that are involved in PIC nuclear import should provide new insight into the molecular mechanisms of the PIC import step and clues to the development of new therapeutics. Furthermore, identification of the factors responsible for this step will assist in our generation of transgenic small animal models that are permissive to HIV-1 infection.

ACKNOWLEDGMENTS

We thank Takao Masuda (Tokyo Dental and Medical University) for providing pNL43luc Δ env and an amphotropic Moloney MuLV envelope expression vector (pJD-1) as well as for critical discussions. We also thank Yoshio Koyanagi (Kyoto University) for providing the 2-LTR plasmid and the AIDS patient serum and for important technical advice. We also thank Yoshio Inagaki (Tokyo Medical and Dental University) for providing the AIDS patient serum. We are grateful

to Luigi Naldini (San Raffaele Telethon Institute for Gene Therapy) and Kenzaburo Tani (Kyushu University) for providing the VSV-G envelope-expressing plasmid (pMD-G).

This work was supported by Grants-in-Aid from the Japan Human Sciences Foundation.

REFERENCES

- Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. *J. Virol.* **59**:284–291.
- Aiken, C. 1997. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. *J. Virol.* **71**:5871–5877.
- Alonso, A., T. P. Cujec, and B. M. Peterlin. 1994. Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1. *J. Virol.* **68**:6505–6513.
- Alonso, A., D. Derse, and B. M. Peterlin. 1992. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. *J. Virol.* **66**:4617–4621.
- Bai, Y., Y. Soda, K. Izawa, T. Tanabe, X. Kang, A. Tojo, H. Hoshino, H. Miyoshi, S. Asano, and K. Tani. 2003. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. *Gene Ther.* **10**:1446–1457.
- Balliet, J. W., D. L. Kolson, G. Eiger, F. M. Kim, K. A. McGann, A. Srinivasan, and R. Collman. 1994. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. *Virology* **200**:623–631.
- Baumann, J. G., D. Unutmaz, M. D. Miller, S. K. Breun, S. M. Grill, J. Mirro, D. R. Littman, A. Rein, and V. N. KewalRamani. 2004. Murine T cells potently restrict human immunodeficiency virus infection. *J. Virol.* **78**:12537–12547.
- Benit, L., N. De Parseval, J. F. Casella, I. Callebaut, A. Cordonnier, and T. Heidmann. 1997. Cloning of a new murine endogenous retrovirus, MuERV-L, with strong similarity to the human HERV-L element and with a gag coding sequence closely related to the Fv1 restriction gene. *J. Virol.* **71**:5652–5657.
- Berson, J. F., D. Long, B. J. Doranz, J. Rucker, F. R. Jirik, and R. W. Doms. 1996. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. *J. Virol.* **70**:6288–6295.
- Best, S., P. Le Tissier, G. Towers, and J. P. Stoye. 1996. Positional cloning of the mouse retrovirus restriction gene Fv1. *Nature* **382**:826–829.
- Bieniasz, P. D., and B. R. Cullen. 2000. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. *J. Virol.* **74**:9868–9877.
- Bouyac-Bertoia, M., J. D. Dvorin, R. A. Fouchier, Y. Jenkins, B. E. Meyer, L. I. Wu, M. Emerman, and M. H. Malim. 2001. HIV-1 infection requires a functional integrase NLS. *Mol. Cell* **7**:1025–1035.
- Browning, J., J. W. Horner, M. Pettoello-Mantovani, C. Raker, S. Yurasov, R. A. DePinho, and H. Goldstein. 1997. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. *Proc. Natl. Acad. Sci. USA* **94**:14637–14641.
- Bukrinsky, M., K. Manogue, and A. Cerami. 1995. HIV results in the frame. Other approaches. *Nature* **375**:195–196. (Author's reply, 375:198.)
- Cherepanov, P., G. Maertens, P. Proost, B. Devreese, J. Van Beumen, Y. Engelborghs, E. De Clercq, and Z. Debyser. 2003. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. *J. Biol. Chem.* **278**:372–381.
- Connor, R. I., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. *Virology* **206**:935–944.
- Cullen, B. R. 2001. Journey to the center of the cell. *Cell* **105**:697–700.
- Depienne, C., A. Mousnier, H. Leh, E. Le Rouzic, D. Dormont, S. Benichou, and C. Dargemont. 2001. Characterization of the nuclear import pathway for HIV-1 integrase. *J. Biol. Chem.* **276**:18102–18107.
- Depienne, C., P. Roques, C. Creminon, L. Fritsch, R. Casseron, D. Dormont, C. Dargemont, and S. Benichou. 2000. Cellular distribution and karyophilic properties of matrix, integrase, and Vpr proteins from the human and simian immunodeficiency viruses. *Exp. Cell Res.* **260**:387–395.
- Farnet, C. M., B. Wang, J. R. Lipford, and F. D. Bushman. 1996. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. *Proc. Natl. Acad. Sci. USA* **93**:9742–9747.
- Fassati, A., D. Gorlich, I. Harrison, L. Zaytseva, and J. M. Mingot. 2003. Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin β . *EMBO J.* **22**:3675–3685.
- Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* **272**:872–877.
- Fouchier, R. A., B. E. Meyer, J. H. Simon, U. Fischer, and M. H. Malim. 1997. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. *EMBO J.* **16**:4531–4539.
- Gabuzda, D. H., H. Li, K. Lawrence, B. S. Vasir, K. Crawford, and E. Langhoff. 1994. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. *J. Acquir. Immune Defic. Syndr.* **7**:908–915.
- Gallay, P., T. Hope, D. Chin, and D. Trono. 1997. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. *Proc. Natl. Acad. Sci. USA* **94**:9825–9830.
- Garber, M. E., and K. A. Jones. 1999. HIV-1 Tat: coping with negative elongation factors. *Curr. Opin. Immunol.* **11**:460–465.
- Garber, M. E., P. Wei, V. N. KewalRamani, T. P. Mayall, C. H. Herrmann, A. P. Rice, D. R. Littman, and K. A. Jones. 1998. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. *Genes Dev.* **12**:3512–3527.
- Goff, S. P. 1996. Operating under a Gag order: a block against incoming virus by the Fv1 gene. *Cell* **86**:691–693.
- Habu, K., J. Nakayama-Yamada, M. Asano, S. Saijo, K. Itagaki, R. Horai, H. Yamamoto, T. Sekiguchi, T. Nosaka, M. Hatanaka, and Y. Iwakura. 1999. The human T cell leukemia virus type I-tax gene is responsible for the development of both inflammatory polyarthropathy resembling rheumatoid arthritis and noninflammatory ankylosing arthropathy in transgenic mice. *J. Immunol.* **162**:2956–2963.
- Hart, C. E., C. Y. Ou, J. C. Galphin, J. Moore, L. T. Bachelier, J. J. Wasmuth, S. R. Petteway, Jr., and G. Schochetman. 1989. Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. *Science* **246**:488–491.
- Hatzioannou, T., S. Cowan, and P. D. Bieniasz. 2004. Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. *J. Virol.* **78**:1006–1011.
- Heinzinger, N. K., M. I. Bukinsky, S. A. Haggerty, A. M. Ragland, V. Kewalramani, M. A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson, and M. Emerman. 1994. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. *Proc. Natl. Acad. Sci. USA* **91**:7311–7315.
- Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene* **77**:51–59.
- Hogan, B., E. Constantini, and E. Lacey. 1994. Manipulating the mouse embryo: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Isegawa, Y., J. Sheng, Y. Sokawa, K. Yamanishi, O. Nakagomi, and S. Ueda. 1992. Selective amplification of cDNA sequence from total RNA by cassette-ligation mediated polymerase chain reaction (PCR): application to sequencing 6.5 kb genome segment of hantavirus strain B-1. *Mol. Cell Probes* **6**:467–475.
- Iwakura, Y., T. Shioda, M. Tosu, E. Yoshida, M. Hayashi, T. Nagata, and H. Shibuta. 1992. The induction of cataracts by HIV-1 in transgenic mice. *AIDS* **6**:1069–1075.
- Jackson, J. B., K. L. MacDonald, J. Cadwell, C. Sullivan, W. E. Kline, M. Hanson, K. J. Sannerud, S. L. Stramer, N. J. Fildes, S. Y. Kwok, et al. 1990. Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1. *N. Engl. J. Med.* **322**:217–222.
- Jolicœur, P., and D. Baltimore. 1976. Effect of Fv-1 gene product on proviral DNA formation and integration in cells infected with murine leukemia viruses. *Proc. Natl. Acad. Sci. USA* **73**:2236–2240.
- Jolicœur, P., and E. Rassart. 1980. Effect of Fv-1 gene product on synthesis of linear and supercoiled viral DNA in cells infected with murine leukemia virus. *J. Virol.* **33**:183–195.
- Kepler, O. T., W. Yonemoto, F. J. Welte, K. S. Patton, D. Iacovides, R. E. Atchison, T. Ngo, D. L. Hirschberg, R. F. Speck, and M. A. Goldsmith. 2001. Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. *J. Virol.* **75**:8063–8073.
- Klatzmann, D., E. Champagne, S. Chamaret, J. Gruet, D. Guetard, T. Hercend, J. C. Gluckman, and L. Montagnier. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. *Nature* **312**:767–768.
- Koito, A., Y. Kameyama, C. Cheng-Mayer, and S. Matsushita. 2003. Susceptibility of mink (*Mustela vison*)-derived cells to replication by human immunodeficiency virus type 1. *J. Virol.* **77**:5109–5117.
- Koito, A., H. Shigekane, and S. Matsushita. 2003. Ability of small animal cells to support the postintegration phase of human immunodeficiency virus type-1 replication. *Virology* **305**:181–191.
- Kukulj, G., K. S. Jones, and A. M. Skalka. 1997. Subcellular localization of avian sarcoma virus and human immunodeficiency virus type 1 integrases. *J. Virol.* **71**:843–847.
- Kwok, S., D. E. Kellogg, N. McKinney, D. Spasic, L. Goda, C. Levenson, and J. J. Sninsky. 1990. Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. *Nucleic Acids Res.* **18**:999–1005.

46. Landau, N. R., M. Warton, and D. R. Littman. 1988. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. *Nature* 334:159-162.
47. Lores, P., V. Boucher, C. Mackay, M. Pla, H. Von Boehmer, J. Jami, F. Barre-Sinoussi, and J. C. Weill. 1992. Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection. *AIDS Res. Hum. Retrovir.* 8:2063-2071.
48. Lu, Y. L., P. Spearman, and L. Ratner. 1993. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. *J. Virol.* 67:6542-6550.
49. Maddon, P. J., A. G. Dalglish, J. S. McDougal, P. R. Clapham, R. A. Weiss, and R. Axel. 1986. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. *Cell* 47:333-348.
50. Maertens, G., P. Cherepanov, W. Pluyms, K. Busschots, E. De Clercq, Z. Debyser, and Y. Engelborghs. 2003. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. *J. Biol. Chem.* 278:33528-33539.
51. Mancebo, H. S., G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, J. Peng, C. Blau, D. Hazuda, D. Price, and O. Flores. 1997. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. *Genes Dev.* 11:2633-2644.
52. Mariani, R., B. A. Rasala, G. Rutter, K. Wieggers, S. M. Brandt, H. G. Krausslich, and N. R. Landau. 2001. Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. *J. Virol.* 75:3141-3151.
53. Mariani, R., G. Rutter, M. E. Harris, T. J. Hope, H. G. Krausslich, and N. R. Landau. 2000. A block to human immunodeficiency virus type 1 assembly in murine cells. *J. Virol.* 74:3859-3870.
54. Masuda, T., V. Planelles, P. Krogstad, and I. S. Chen. 1995. Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. *J. Virol.* 69:6687-6696.
55. Miller, D. G., and A. D. Miller. 1994. A family of retroviruses that utilize related phosphate transporters for cell entry. *J. Virol.* 68:8270-8276.
56. Morikawa, Y., S. Hinata, H. Tomoda, T. Goto, M. Nakai, C. Aizawa, H. Tanaka, and S. Omura. 1996. Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding. *J. Biol. Chem.* 271:2868-2873.
57. Neil, S., F. Martin, Y. Ikeda, and M. Collins. 2001. Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. *J. Virol.* 75:5448-5456.
58. Newstein, M., E. J. Stanbridge, G. Casey, and P. R. Shank. 1990. Human chromosome 12 encodes a species-specific factor which increases human immunodeficiency virus type 1 tat-mediated trans activation in rodent cells. *J. Virol.* 64:4565-4567.
59. Nisole, S., and A. Saib. 2004. Early steps of retrovirus replicative cycle. *Retrovirology* 1:9.
60. Nisole, S., J. P. Stoye, and A. Saib. 2005. TRIM family proteins: retroviral restriction and antiviral defence. *Nat. Rev. Microbiol.* 3:799-808.
61. Nomura, H., B. W. Nielsen, and K. Matsushima. 1993. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. *Int. Immunol.* 5:1239-1249.
62. Ory, D. S., B. A. Neugeboren, and R. C. Mulligan. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/viral stromatitis virus G pseudotypes. *Proc. Natl. Acad. Sci. USA* 93:11400-11406.
63. Petit, C., O. Schwartz, and F. Mammano. 2000. The karyophilic properties of human immunodeficiency virus type 1 integrase are not required for nuclear import of proviral DNA. *J. Virol.* 74:7119-7126.
64. Piller, S. C., L. Caly, and D. A. Jans. 2003. Nuclear import of the pre-integration complex (PIC): the Achilles heel of HIV? *Curr. Drug Targets* 4:409-429.
65. Planelles, V., A. Haislip, E. S. Withers-Ward, S. A. Stewart, Y. Xie, N. P. Shah, and I. S. Chen. 1995. A new reporter system for detection of retroviral infection. *Gene Ther.* 2:369-376.
66. Pluyms, W., P. Cherepanov, D. Schols, E. De Clercq, and Z. Debyser. 1999. Nuclear localization of human immunodeficiency virus type 1 integrase expressed as a fusion protein with green fluorescent protein. *Virology* 258:327-332.
67. Pollard, V. W., and M. H. Malim. 1998. The HIV-1 Rev protein. *Annu. Rev. Microbiol.* 52:491-532.
68. Popov, S., M. Rexach, G. Zybarrh, N. Reiling, M. A. Lee, L. Ratner, C. M. Lane, M. S. Moore, G. Blobel, and M. Bukrinsky. 1998. Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. *EMBO J.* 17:909-917.
69. Sakai, H., R. Shibata, J. Sakuragi, S. Sakuragi, M. Kawamura, and A. Adachi. 1993. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. *J. Virol.* 67:1663-1666.
70. Sawada, S., K. Gowrishankar, R. Kitamura, M. Suzuki, G. Suzuki, S. Tahara, and A. Koito. 1998. Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. *J. Exp. Med.* 187:1439-1449.
71. Sherman, M. P., and W. C. Greene. 2002. Slipping through the door: HIV entry into the nucleus. *Microbes Infect.* 4:67-73.
72. Stremiau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. *Nature* 427:848-853.
73. Suzuki, Y., N. Misawa, C. Sato, H. Ebina, T. Masuda, N. Yamamoto, and Y. Koyanagi. 2003. Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells. *Virus Genes* 27:177-188.
74. Tanaka, J., H. Ozaki, J. Yasuda, R. Horai, Y. Tagawa, M. Asano, S. Saijo, M. Imai, K. Sekikawa, M. Kopf, and Y. Iwakura. 2000. Lipopolysaccharide-induced HIV-1 expression in transgenic mice is mediated by tumor necrosis factor-alpha and interleukin-1, but not by interferon-gamma nor interleukin-6. *AIDS* 14:1299-1307.
75. Tsuruo, T., T. Yamori, K. Naganuma, S. Tsukagoshi, and Y. Sakurai. 1983. Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. *Cancer Res.* 43:5437-5442.
76. Tsurutani, N., M. Kubo, Y. Maeda, T. Ohashi, N. Yamamoto, M. Kannagi, and T. Masuda. 2000. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. *J. Virol.* 74:4795-4806.
77. van Maanen, M., and R. E. Sutton. 2003. Rodent models for HIV-1 infection and disease. *Curr. HIV Res.* 1:121-130.
78. Wei, P., M. E. Garber, S. M. Fang, W. H. Fischer, and K. A. Jones. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell* 92:451-462.
79. Yang, W. K., J. O. Kiggans, D. M. Yang, C. Y. Ou, R. W. Tennant, A. Brown, and R. H. Bassin. 1980. Synthesis and circularization of N- and B-tropic retroviral DNA Fv-1 permissive and restrictive mouse cells. *Proc. Natl. Acad. Sci. USA* 77:2994-2998.
80. Yasuda, J., T. Miyao, M. Kamata, Y. Aida, and Y. Iwakura. 2001. T cell apoptosis causes peripheral T cell depletion in mice transgenic for the HIV-1 vpr gene. *Virology* 285:181-192.
81. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. *Cell* 61:213-222.
82. Zennou, V., C. Petit, D. Guetard, U. Nerhass, L. Montagnier, and P. Charneau. 2000. HIV-1 genomic nuclear import is mediated by a central DNA flap. *Cell* 101:173-185.
83. Zheng, Y. H., H. F. Yu, and B. M. Peterlin. 2003. Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. *Nat. Cell Biol.* 5:611-618.

Hematopoietic stem cell–engrafted NOD/SCID/IL2R γ ^{null} mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses

Satoru Watanabe,¹ Kazuo Terashima,² Shinrai Ohta,³ Shigeo Horibata,³ Misako Yajima,⁴ Yoko Shiozawa,¹ M. Zahidunnabi Dewan,^{2,3} Zhong Yu,² Mamoru Ito,⁵ Tomohiro Morio,⁶ Norio Shimizu,¹ Mitsuo Honda,³ and Naoki Yamamoto^{2,3}

¹Department of Virology, Division of Medical Science, Medical Research Institute, Tokyo Medical and Dental University, Japan; ²Department of Molecular Virology, Graduate School of Medicine, Tokyo Medical and Dental University, Japan; ³AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan; ⁴Department of Infectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan; ⁵Central Institute for Experimental Animals, Kanagawa, Japan; and ⁶Department of Pediatrics and Developmental Biology, Graduate School of Medicine, Tokyo Medical and Dental University, Japan

Critical to the development of an effective HIV/AIDS model is the production of an animal model that reproduces long-lasting active replication of HIV-1 followed by elicitation of virus-specific immune responses. In this study, we constructed humanized nonobese diabetic/severe combined immunodeficiency (NOD/SCID)/interleukin-2 receptor γ -chain knockout (IL2R γ ^{null}) (hNOG) mice by transplanting human cord blood–derived hematopoietic stem cells that eventually developed into human B cells, T cells, and other monocytes/macrophages and dendritic

cells associated with the generation of lymphoid follicle–like structures in lymphoid tissues. Expressions of CXCR4 and CCR5 antigens were recognized on CD4⁺ cells in peripheral blood, the spleen, and bone marrow, while CCR5 was not detected on thymic CD4⁺ T cells. The hNOG mice showed marked, long-lasting viremia after infection with both CCR5- and CXCR4-tropic HIV-1 isolates for more than the 40 days examined, with R5 virus-infected animals showing high levels of HIV-DNA copies in the spleen and bone marrow, and X4 virus-infected animals

showing high levels of HIV-DNA copies in the thymus and spleen. Furthermore, we detected both anti-HIV-1 Env gp120- and Gag p24-specific antibodies in animals showing a high rate of viral infection. Thus, the hNOG mice mirror human systemic HIV infection by developing specific antibodies, suggesting that they may have potential as an HIV/AIDS animal model for the study of HIV pathogenesis and immune responses. (Blood. 2007; 109:212-218)

© 2007 by The American Society of Hematology

Introduction

Current animal models for either human immunodeficiency virus type 1 (HIV-1) or simian immunodeficiency virus (SIV) suffer from the lack of a system precisely mirroring human HIV infection and the progression to disease state.¹ In current animal models with HIV infection, such as chimpanzees, animals do not develop AIDS.¹ Past animal models for HIV infection have relied on humanized severe combined immunodeficiency (hSCID) mice models to study prospective anti-HIV drugs and vaccines. SCID-hu (Thy/Liv) mice, engrafted with human fetal thymus and liver tissue in the renal subcapsular region, were first reported as the small-animal model.² Because human T cells are generated within the engrafted thymus, this model has been used for the study of thymopoiesis³⁻⁶ and hematopoiesis^{7,8} under the burden of HIV-1 infection. However, this model allows for a limited systemic HIV-1 infection, which is restricted mainly to the engrafted thymus. Another HIV mouse model, hu-PBL-SCID mice engrafted with human peripheral blood mononuclear cells (PBMCs),⁹ has been actively used as a tool in developing antiretroviral therapy.⁹⁻¹¹ However, the infection persists for only a short time in association with rapid loss of CD4⁺ T cells because there is no active hematopoiesis or thymopoiesis.^{9,12,13} Furthermore, these mouse

models fail to mirror certain key aspects of the human immune response, lacking normal lymphoid tissue and functional human antigen-presenting cells such as dendritic cells (DCs).¹⁴ Thus, although these mouse models are valuable as animal models for HIV infection, the development of a mouse model more analogous to human HIV infection is needed if we are to better understand HIV pathogenesis and develop successful anti-HIV therapies and preventive vaccines.

To solve the difficult issue about the development of an ideal HIV mouse model, we initially selected a humanized nonobese diabetic (NOD)/SCID interleukin-2 receptor (IL-2R) γ -chain knockout (NOG) mouse¹⁵ as a model animal because it has been suggested that multilineage cells, including human T, B, and natural killer (NK) cells, differentiate in these mice when given transplants of human CD34⁺ hematopoietic stem cells.¹⁶⁻¹⁸ In the current study, we further reveal the kinetics of differentiation of human B and T cells, monocytes/macrophages, and DCs in the mice that received transplants, and we characterize the animals by infection with both CCR5 (R5)- and CXCR4 (X4)-tropic HIV strains. Since our hNOG mice show stable and systemic infection of both R5- and X4-tropic HIV for more than

Submitted April 20, 2006; accepted August 12, 2006. Prepublished online as *Blood* First Edition Paper, September 5, 2006; DOI 10.1182/blood-2006-04-017681.

The publication costs of this article were defrayed in part by page charge

payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2007 by The American Society of Hematology

the 40 days studied, and HIV-specific antibodies are detectable in the animals with high plasma viral loads and HIV-DNA copy numbers, we also discuss the suitability of HIV-hNOG mice as an animal model for HIV-1 infection.

Materials and methods

Transplantation of human CB-derived hematopoietic stem cells in NOG mice

Human cord blood (CB) was obtained from Saiseikai Central hospital (Minato-ku, Tokyo, Japan) and Tokyo Cord Blood Bank (Katsushika-ku, Tokyo, Japan) after obtaining informed consent. All research on human subjects was approved by the Institutional Review Board of each institution participating in the project. CB mononuclear cells were separated by Ficoll-Hypaque density gradient. CD34⁺ hematopoietic stem cells were isolated using a magnetic-activated cell sorting (MACS) Direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. More than 95% of CD34⁺ cells were positively selected after 2 time-enrichment manipulations. Cells were either immediately used for the transplantation or frozen until use. NOG mice were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan) and maintained under specific pathogen-free (SPF) conditions in the animal facility of the National Institute of Infectious Diseases (NIID; Tokyo, Japan). Mice used in these studies were free of known pathogenic viruses, herpes viruses, bacteria, and parasites. They were housed in accordance with the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Science (1987) under the Japanese Law Concerning the Protection and Management of Animals, and were maintained in accordance with the guidelines set forth by the Institutional Animal Care and Use Committee of NIID, Japan. Once approved by the Institutional Committee for Biosafety Level 3 experiments, these studies were conducted at the Animal Center, NIID, Japan, in accordance with the requirements specifically stated in the laboratory biosafety manual of the World Health Organization. Female mice (6 to 10 weeks old) were irradiated (300 cGy) and 1×10^4 to 1.2×10^5 CD34⁺ cells were intravenously injected within 12 hours.

Flow cytometry

The purity of CB-derived CD34⁺ cells after separation was evaluated by double staining with FITC-conjugated anti-human CD45 (J.33) and PE-conjugated anti-human CD34 (Class III 581) (all from Beckman Coulter, Fullerton, CA). After transplantation (1-7 months), peripheral blood, spleens, bone marrow (BM), and thymi were collected for flow cytometric analysis following staining with the following monoclonal antibodies (mAbs): FITC-conjugated anti-human CD45 (J.33), CD3 (UCHT1), CD4 (13B8.2), CD19 (J4.119), CD45RO (UCHL1) (all from Beckman Coulter), and CCR5 (2D7; BD Pharmingen, San Diego, CA); PE-conjugated anti-human CD4 (13B8.2), CD8 (B9.11), CD19 (J4.119), CD45RA (ALB11) (all from Beckman Coulter), and CXCR4 (44717; R&D Systems, Minneapolis, MN); anti-mouse CD45 (YW62.3; Beckman Coulter); ECD-conjugated anti-human CD45 (J.33; Beckman Coulter); and PC5-conjugated anti-human CD8 (T8) and CD14 (Rm052) (all from Beckman Coulter). Flow cytometric analysis was conducted by 2- or 4-color staining using an EpicsXL (Beckman Coulter).

Immunohistochemistry

Organs were snap-frozen following embedding in OCT compound (Sakura Finetechnical, Tokyo, Japan). Frozen sections were air-dried and fixed in acetone. HIV-1-infected organs were fixed in 4% paraformaldehyde and embedded in OCT compound following immersion in gradient sucrose (5%-30%). Fixed samples were stained with the following mAbs: anti-human CD45 (1.22/4014; Nichirei, Tokyo, Japan), CD3 (UCHT1; DAKO, Glostrup, Denmark), CD20 (L26; DAKO), CD68 (KP1; DAKO), CD205 (MG38; eBioscience, San Diego, CA), and DRC-1 (R4/23; DAKO) for follicular dendritic cells (FDCs); anti-mouse FDC-M1 (BD Pharmingen)

for murine FDCs; and HIV-1 Gag p24 (DAKO) for detection of infected cells. Biotin-labeled goat F(ab')₂ anti-mouse immunoglobulin (Ig; ICN Biomedicals, Aurora, OH) or biotin-labeled mouse F(ab')₂ anti-rat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) was used as the secondary antibody. Samples were treated with alkaline phosphatase (AP) or horseradish peroxidase (HRP)-streptavidin conjugate (ZYMED Laboratories Inc, San Francisco, CA). BCIP/NBT, DAB, or AEC (all from DAKO) was used for the visualization. Photographs were taken by light microscopy (Leica DMRA; Leica Microsystems Wetzlar, Wetzlar, Germany) using Leica HC PLAN APO lenses (10×/0.40 NA PH1). Leica Q550 was used for image processing.

Measurement of human Igs in mice plasma

Plasma concentrations of human IgM, IgG, and IgA in NOG mice that received transplants of human stem cells were determined by conventional human Ig quantitation assay at BML Inc (Tokyo, Japan).

Cells and viruses

Human embryonic kidney 293T cells and monkey kidney COS7 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and antibiotics. The 293T cells and COS7 cells were used for transfection of DNA plasmids containing HIV-1_{JRC5F} and simian/human immunodeficiency virus (SHIV)-C2/1, respectively. The SHIV-C2/1 strain contains the *env* gene of pathogenic HIV-1 strain 89.6.¹⁹ Cell-free supernatant was collected and stored at -80°C before use. A primary clinical isolate, HIV-1_{MNP}, was kindly provided by Dr J. Sullivan of the University of Massachusetts Medical School (Worcester, MA). PBMCs isolated from HIV-1-seronegative individuals were cultured in RPMI 1640 supplemented with 10% FBS and antibiotics with 5 μg of phytohemagglutinin (PHA)/mL for 3 or 7 days (PHA-PBMCs). HIV-1_{MNP} was propagated in PHA-PBMCs, and cell-free virus stocks were stored at -80°C.

The 50% tissue-culture infectious dose (TCID₅₀) was determined using PHA-PBMCs and the endpoint dilution method. A 4-fold series of dilution was prepared from the virus stock, and then cells were mixed and cultured for 7 days for X4-HIV-1 and 14 days for R5-HIV-1 in RPMI 1640 supplemented with 20% FBS and antibiotics. The endpoints were determined by screening for the p24 antigen using Lumipulse (Fujirevio, Tokyo, Japan).

HIV-1 infection

All procedures for the infection and maintenance of NOG mice were performed in Biosafety Level 3 facilities at NIID under standard caging conditions. On days 102 to 132 after stem cell transplantation, 16 mice were inoculated intravenously with R5-tropic HIV-1_{JRC5F} (65 000 TCID₅₀) or X4-tropic SHIV-C2/1 (50 000 TCID₅₀). On days 18 to 43 after inoculation, plasma was collected to determine HIV-RNA copy numbers, and spleen cells were prepared as single-cell suspensions to analyze the CD4/CD8 ratio using flow cytometry. A number (14) of other mice were inoculated intravenously with R5-tropic HIV-1_{JRC5F} (200 or 65 000 TCID₅₀) or X4-tropic HIV-1_{MNP} (180 or 20 000 TCID₅₀) on days 126 to 146 after transplantation. On days 18 to 40 after inoculation, plasma was collected for the determination of HIV-RNA copy numbers, and single-cell suspensions of the spleen, BM, and thymus were prepared for HIV-DNA measurement. The CD4/CD8 ratio in the spleen and percentages of human CD45⁺ cells in organs were analyzed using flow cytometry.

Virologic analysis

Plasma viral RNA copy numbers were measured using a real-time quantification assay based on the TaqMan system (Applied Biosystems, Foster City, CA). Plasma viral RNA was extracted and purified using a QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA). The RNA was subjected to reverse transcription (RT) and amplification using a TaqMan One-Step RT-polymerase chain reaction (PCR) Master Mix Reagents Kit (PE Biosystems, Foster City, CA) with HIV-1 gag consensus primers

(forward, 5'-GGACATCAAGCAGCCATGCAA-3'; and reverse, 5'-TGCTATGTCCTCCCTTGG-3') and an HIV-1 gag consensus TaqMan probe (FAM-5'-ACCATCAATGAGGAAGCTGCAGAA-3'-TAMRA). For SHIV-C2/I analysis, primers (forward, 5'-AATGCAGAGCCCCAAGAC-3'; and reverse, 5'-GGACCAAGGCCTAAAAACCC-3') and a TaqMan probe (FAM-5'-ACCATGTTATGGCCAAATGCCAGAC-3'-TAMRA) were designed for targeting the SIVmac239 gag region.²⁰ Probed products were quantitatively monitored by their fluorescence intensity with the ABI7300 Real-Time PCR system (PE Biosystems). To obtain control RNA for quantification, HIV-1 gag RNA and SIVmac239 gag RNA were synthesized using T7 RNA polymerase and pKS460. Viral DNA was extracted and purified using a QIAamp DNA Mini Kit (Qiagen). Determination of HIV-1 DNA copy numbers was performed by real-time PCR assay with TaqMan Master mixture (PE Biosystems). Primers (forward, 5'-GGCTAACTAGGGAACCCACTG-3'; and reverse, 5'-CTGCTAGAGATTTCCACACT-3') and probes (FAM-5'-TAGTGTGTGCCGTCTGTTGTGTGAC-3'-TAMRA) were designed for targeting the HIV-1 long terminal repeat region. R/U5. The viral DNA was quantified using LightCycler (Roche Diagnostics, Almere, The Netherlands). Viral RNA and DNA were calculated based on the standard curve of control RNA and DNA. All assays were carried out in duplicate.

HIV-antigen ELISA

Levels of anti-HIV-1 Igs against recombinant HIV-1_{IIIB} Env gp120, recombinant HIV-1_{MAN} Env gp120, and recombinant HIV-1_{IIIB} Gag p24 (all from ImmunoDiagnostics Inc. Woburn, MA) in plasma from HIV-1-infected and -uninfected control mice were determined using a standard enzyme-linked immunosorbent assay (ELISA). Microplates (96-well) were coated overnight with 200 ng/well antigens, and plasma diluted 1:20, 1:60, and 1:180 with PBS were incubated for 1 hour. AP-labeled anti-human Igs (γ , α , and μ ; Sigma-Aldrich, St Louis, MO) were used as secondary antibodies. P-nitrophenylphosphate (pNPP) Solution (WAKO Chemical USA, Richmond, VA) was used for the visualization. The enzyme reaction was stopped by addition of 0.1 M NaOH and read at 405 nm. All assays were carried out in triplicate.

Statistical analysis

Data were expressed as the mean value \pm standard deviation (SD). Significant differences between data groups were determined by 2-sample Student *t* test analysis. A *P* value less than .05 was considered significant.

Results

Reconstitution of human lymphoid systems in hNOG mice

The initial studies describing the construction of humanized SCID mice used the human PBMC for infection of immunodeficiency viruses.^{9,12,21} However, these hu-PBL-SCID mice showed a partial infection to the R5 virus and a relatively limited period of viral replication. To construct a more suitable mouse model mimicking HIV-1 infection in humans, we selected human CB stem cells as a transplant for NOG mice. NOG mice were inoculated intravenously with human CD34⁺ hematopoietic stem cells, and their development of human lymphoid systems were then monitored. After transplantation (2 months), human CD45⁺ leukocytes were recognized in both PB and the spleen, but most of the cells were human B cells (Figure 1A). Human T cells began to be recognized clearly in PB and the spleen 4 months after transplantation (Figure 1B) and gradually increased in level, as did human B cells (Figure 1C).

In Figure 1D, we summarized percentages of human CD3⁺ T cells in human CD45⁺ cells from 38 mice from 39 to 213 days after transplantation. Human CD3⁺ T cells clearly increased 100 days after transplantation in both PB and the spleen. After transplanta-




Figure 1. Flow cytometric analysis of human T cells in the peripheral blood and spleen in NOG mice given intravenous transplants of human CB-derived CD34⁺ cells. (A-C) Representative profiles of the mice 2 months (A), 4 months (B), and 7 months (C) after transplantation. The ratio of human to murine CD45⁺ cells and that of human CD3⁺ to CD19⁺ cells show an incremental increase in human CD45⁺ cells and human CD3⁺ cells from 2 to 7 months. (D) Change of net percentages of human CD3⁺ T cells among human CD45⁺ cells in peripheral blood and the spleen from 38 mice 39 to 213 days after transplantation. (E) CD45RA is more efficiently expressed than CD45RO on human CD3⁺ T cells in spleen. A gate was set on the human CD45⁺ population. The fluorescence-activated cell sorting (FACS) profile is representative of 1 in a group of 5 mice.

tion (4 months), human CD3⁺ T cells in the spleen preferably expressed CD45RA rather than CD45RO (70.8% \pm 13.4% and 27.3% \pm 38.8% in CD3⁺ T cells, respectively; *n* = 5; Figure 1E), demonstrating that most of the T cells were in a naive state. In addition, plasma taken from 5 mice 113 to 143 days after transplantation showed that all mice produced human IgM, with concentrations ranging from 0.025 to 0.5 g/L, and that human IgG and IgA was also detected in some of the mice (ranges, 0.015-0.18 g/L and 0.003-0.012 g/L, respectively) (data not shown).

By 7 months after transplantation, human CD45⁺ leukocytes comprised more than 80% to 90% of mononuclear cells in the spleen (Figure 1C), and most of the mice showed symptoms of a wasting condition and a hunched back. Based upon these results, we determined that the suitable period for HIV inoculation would be 4 to 5 months after transplantation.

Formation of lymphoid structures, including monocytes/macrophages, DCs, and FDCs

Next, using the hNOG mice at 4 months after transplantation, we investigated lymphoid structure formation and the development of human monocytes, macrophages, DCs, and FDCs, which are very important factors not only for elicitation of immune responses against foreign antigens, but also for the spread of HIV-1 infection in a body.²²⁻²⁴ Human CD14⁺ monocytes were detected in PB, the spleen, and BM using flow cytometry (Figure 2A). During immunohistochemical analysis, human CD45⁺ leukocytes gathered in a form of follicle-like structures (FLSs) at the end of the central artery in the spleen (Figure 2B). From a serial section of the same region (Figure 2B-G), these structures consisted mainly of human CD20⁺ B cells (Figure 2C) admixed with a small number of human CD3⁺ T cells (Figure 2D). Hardly any human FDCs positive for DRC-1 were detected (data not shown), whereas a




Figure 2. Flow cytometric analysis and immunohistochemical analysis of the expression of myelomonocytic markers in hNOG mice 4 months after transplantation. (A) Human CD14⁺ monocytes/macrophages are recognized in peripheral blood, the spleen, and BM. (B-G) Immunohistochemical findings from serially sectioned spleen for the expressions of human CD45 (B), human CD20 (C), human CD3 (D), murine FDC (E), human CD205 (F), and human CD68 (G). (H) Human CD68⁺ macrophages are also detected in the medulla of the LN and lung. Visualization was performed with BCIP (B-D, F-G), DAB (E), and AEC (H). Original magnification, $\times 100$.

loose network of murine FDCs positive for FDC-M1 was recognized in the distal portion of the FLSs (Figure 2E). Human CD205⁺ DCs were predominantly detected in a cluster form within the FLSs (Figure 2F), while human CD68⁺ macrophages were scattered throughout the spleen (Figure 2G). Many human CD68⁺ macrophages were also observed in various other organs, including the lymph nodes (LNs) and the lungs (Figure 2H).

Expression of HIV-1 coreceptors on CD4⁺ cells in various tissues

Since the development of lymphoid tissues was recognized in hNOG mice, we focused on the expressions of HIV-1 coreceptors CXCR4 and CCR5 on human CD4⁺ cells in these tissues. CXCR4 antigen was expressed in $36.5\% \pm 4.2\%$ (n = 4) of the CD4⁺ cells in PB (Figure 3A) and $78.1\% \pm 17.1\%$ (n = 5) in the spleen (Figure 3B). CCR5⁺ cells were detected in $15.5\% \pm 1.8\%$ (n = 4) of CD4⁺ cells in PB and $28.6\% \pm 12.6\%$ (n = 5) in the spleen (Figure 3A-B). In the thymus, CD4⁺CD8⁺ thymocytes existed in $82.9\% \pm 4.4\%$ (n = 5) as well as small numbers of CD4⁺CD8⁻ cells ($6.4\% \pm 2.4\%$; n = 5) and CD4⁻CD8⁺ cells ($7.7\% \pm 3.0\%$; n = 5), with the CXCR4 antigen expressed in $50.1\% \pm 4.5\%$ (n = 5) of CD4⁺ cells, while, as with normal human thymocytes,²⁵ CCR5⁺ cells were almost undetectable, with less than 1% ($0.6\% \pm 0.1\%$; n = 5) (Figure 3C). Human CD3⁺ T cells and CD14⁺ monocytes in BM were detected only in $3.2\% \pm 2.1\%$ and $5.8\% \pm 3.8\%$, respectively, while CD4⁺ cells were recognized in $18.1\% \pm 6.5\%$, with many expressing both CXCR4 ($75.0\% \pm 23.1\%$) and CCR5 ($81.3\% \pm 6.6\%$; n = 5; Figure 3D). Thus, distributions of HIV-1 coreceptor-positive cells in these

lymphoid tissues suggest that the hNOG mice allow for sufficient development of human cells to make the study of HIV-1 pathogenesis possible.

Both R5- and X4-tropic HIVs efficiently infect and replicate in hNOG mice

In our preliminary study, using low and high doses of challenge virus, no viral infection was detected in any of the virus-inoculated hNOG mice at 7 days after infection, while some showed detectable plasma viral loads at 14 days (data not shown). Then, we prepared 16 hNOG mice that received transplants of stem cells and inoculated them with a high dose of R5-tropic HIV-1_{JRCSF} (65 000 TCID₅₀) and X4-tropic SHIV-C2/1 (50 000 TCID₅₀) intravenously through the tail vein at 102 to 132 days after transplantation. Upon HIV-1_{JRCSF} infection, viral copy numbers in plasma rose to a level of 1.6×10^5 to 5.8×10^5 copies/mL (n = 4) on day 33 and 2.0×10^5 to 4.7×10^5 copies/mL on day 43 (n = 4) (Figure 4A). Moreover, for SHIV-C2/1 infection, viral copy numbers in plasma were 1.6×10^3 to 3.2×10^5 copies/mL on day 18 (n = 4) and reached 5.4×10^4 to 1.1×10^5 copies/mL on day 42 (n = 4; Figure 4B). In these mice, no significant decline in the CD4/CD8 ratio was observed throughout entire period of follow-up for the R5-tropic virus infection, while CD4⁺ cell decline was detected for the X4-tropic virus infection on day 42 after infection (P = .044) but not on day 18 after infection (Figure 4C). Four mice that did not receive transplants of human stem cells showed no detectable levels of plasma viral load (less than 500 copies/mL) following HIV/SHIV inoculation (data not shown).

To confirm HIV infection, we used immunohistochemistry to detect the presence of the p24 antigen of the HIV-1 Gag protein in various tissues of mice showing viremia. p24⁺ cells were clearly identified in the spleen, LN, and lungs (Figure 4D), which include macrophage-like cells.

Different distributions of R5- and X4-tropic viruses in lymphoid tissues

A number of mice (14) were further analyzed for HIV-1 infection on days 126 to 146 after transplantation with a low dose (200 TCID₅₀) or a high dose (65 000 TCID₅₀) of R5-tropic HIV-1_{JRCSF} and a low dose (180 TCID₅₀) or a high dose (20 000 TCID₅₀) of X4-tropic HIV-1_{MNP}. Consequently, 2 of the 4 mice given a low




Figure 3. Surface expression of HIV-1 coreceptors on CD4⁺ cells in various organs of mice 4 months after transplantation. A representative FACS profile of human CXCR4 and CCR5 on CD4⁺ cells shows the existence of CXCR4⁺CD4⁺ and CCR5⁺CD4⁺ cells in blood (A), spleen (B), and BM (D), but no CCR5⁺CD4⁺ cells in the thymus (C). BM results show that many CD4⁺ cells are neither CD3⁺ T cells nor CD14⁺ monocytes. A gate was set on the human CD45⁺ population.